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1. Introduction 
 
Fluoroquinolone resistance is emerging in Gram-negative pathogens, as reported in 2009 by 
the European Antimicrobial Resistance Surveillance Network that highlighted over 20% of 
invasive Escherichia coli isolates were resistant to fluoroquinolones in Europe. In Italy, Spain, 
Portugal, Hungary, Bulgaria and Cyprus the resistance rates exceeded 25% (1). In 2003, a survey 
of enteric bacteria in US intensive care units found more than 10% of these organisms to be 
resistant to ciprofloxacin (2). In 1999, a study found about 25% of healthy individuals living in 
Barcelona to be intestinally colonised with quinolone-resistant Escherichia coli (3). Levels of 
quinolone resistance in clinical E. coli isolates have been reported at 40% in Hong Kong in 2006 
(4). These increasing numbers of resistant Enterobacteriaceae isolates worldwide are hardly 
explained only by chromosomal mutations, the traditional way of developing resistance to 
fluoroquinolones. The recent discovery of plasmid-mediated horizontally transferable genes 
encoding quinolone resistance might shed light on these phenomena (5). 
Quinolones were introduced into clinical use in 1962 in the form of nalidixic acid, a total 
syntethic agent. Pharmacological improvements of the basic quinolone molecule resulted in 
fluoroquinolones (Figure 1), which became clinically available in the 1980s (6). Nowadays, 
several members of this antimicrobial agent group are used worldwide, since they possess 
excellent activity against Enterobacteriaceae and are the recommended therapy according to both 
CLSI and EUCAST (7, 8). 
Over the decades, Enterobacteriaceae developed resistance to these agents, resulting in 
clinical therapy failure. Resistance to quinolones and fluoroquinolones is generally due to 
chromosomal mutations in genes coding for the target molecules of these agents, namely the 
DNA gyrase and topoisomerase IV enzymes. Both have characteristic sequences in their genes, 
called quinolone resistance determining regions (QRDR), where mutations occur. Interpretation 
of a pathogen as ’resistant’ depends on the internationally approved breakpoints: the EUCAST 
ciprofloxacin breakpoint for Enterobacteriaceae is 1µg/ml (8, 9). However, low-level resistance 
corresponding to minimal inhibitory concentration (MIC) values exceeding those of wild-type E. 
coli but still below the resistance breakpoint (Figure 3), not necessarily entail mutations in the 
target molecules (9). Spontaneus chromosomal mutations occur in one out of 108 - 109 cells, and 
double mutations required for clinically important ciprofloxacin resistance are even rarer events, 
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one from 1014 (10, 11). Mutation frequency is 100 times higher in bacterial cells in low-level 
resistance, facilitating the selection to higher resistance levels (12). Permeability of Gram-
negative cell wall to fluoroquinolones was described; notably, in rough lipopolysaccharide (LPS) 
mutants of Salmonella typhimurium MICs to hydrophobic quinolones like nalidixic acid are 2-4 
folds lower than the smooth LPS-variant, but MICs to hydrophilic ones (e.g: ciprofloxacin and 
norfloxacin) are not affected (13). In the case of OmpF mutants of E. coli the MIC of nalidixic 
acid, norfloxacin and ciprofloxacin had a two-fold increase, i.e. in the range of low-level 
resistance (13, 14). Active efflux systems (acrAB-TolC) resulting in decreased intracellular 
accumulation of fluoroquinolones in Escherichia coli and Klebsiella pneumoniae were detected 
(15, 16, 17, 18, 19). 
In 1998, the first plasmid-mediated quinolone resistance (PMQR) determinant, the qnr gene, 
was discovered on a transferable plasmid of a K. pneumoniae human clinical isolate, after 
conjugation causing low-level resistance in recipient strains (12). Later on, other plasmidic genes 
were described conferring low-level fluoroquinolone resistance, such as ciprofloxacin modifying 
enzyme, the cr variant of aminoglycoside-acetyltransferase(6’)-Ib in 2006 and fluoroquinolone 
specific efflux pumps, qepA being the first detected in 2007 followed in 2009 by oqxAB (20, 21, 
22). 
Plasmids, defined as bacterial extrachromosomal, doublestranded, circular DNA molecules 
capable of autonomous replication have crucial role in the dissemination of resistance genes like 
extended-spectrum beta-lactamase (ESBL) and PMQR genes (23). Nevertheless, association 
between these two resistance mechanisms in Enterobacteriaceae has been detected worldwide (5, 
24, 25, 26). These findings are alarming, since ESBLs confer resistance to third generation 
cefalosporins, while PMQR causes low-level fluoroquinolone resistance. These antimicrobial 
agents are in the first line of option for several infectious diseases (e.g. urinary tract infections 
and pneumonia). If they are found to be ineffective because of resistance, clinicians will face 
worrisome situations. 
 
1.1 Quinolone and fluoroquinolone antimicrobial agents 
Quinolones and fluoroquinolones are effective antimicrobial agents showing different efficacy 
against infections. Nalidixic acid is a quinolone agent effective against Enterobacteriaceae in the 
site of urinary tract, since it reaches therapeutically active concentrations only there (27).  
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Pharmacological improvements on the basic quinolone ring with the addition of fluorin at 
position C6 and piperazynil or related rings at position C7 yielded the fluoroquinolones (Figure 
1). Several agents are used in clinical practice such as norfloxacin, ciprofloxacin, levofloxacin 
and moxifloxacin. They achieve higher serum levels leading to better tissue penetration and more 
potency against Enterobacteriaceae and other species (6, 27). 
Norfloxacin and ciprofloxacin are active against several Gram-negative bacteria (besides 
Enterobacteriaceae they can be used successfully also against other pathogens like Neisseria 
gonorrhoeae), generally used in urinary tract infections (e.g.: cystitis, urethritis). Ciprofloxacin is 
active against Pseudomonas aeruginosa and also used against enteric infections of Salmonella 
spp. and Shigella spp. Levofloxacin and moxifloxacin have therapeutically active concentration 
at the respiratory tract and show therapeutic activity against Gram-positive bacteria as well (e.g.: 
Staphylococcus aureus, Streptococcus pneumoniae), these features make them useful in lower 
respiratory tract infections such as pneumonia. Antimicrobial spectrum of moxifloxacin includes 
anaerobic bacteria too (e.g.: Bacteroides spp. and Clostridium spp.) (27). 
Adverse effects of fluoroquinolone therapy are rare, including fotosensitivity and with allergic 
reactions developing only in less than 0.5% of the population. Joint cartilage formation was 
damaged when ciprofloxacin was experimentally administered in animals, therefore treatment 
with fluoroquinolones is not recommended for pregnant, breastfeeding women and children 
under age sixteen (27). 
 
 
Figure 1. Overview of fluoroquinolones frequently used in clinical practice (5). 
Basic quinolone chemical structure, 
with fluorin at position C6. 
Addition of substituents at position 
C7. Active in respiratory tract 
infections mainly against Gram-
positive bacteria. 
Addition of piperazynil ring at 
position C7. Active in urinary tract 
infections against Gram-negative 
bacteria. 
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1.2 Mechanism of action of fluoroquinolones is the inhibition of type II topoisomerase enymes, 
namely gyrase and topoisomerase IV. Both of them are involved in the bacterial DNA replication 
(Figure 2); gyrase introduces negative supercoils (or relaxes positives) into DNA by looping, 
topoisomerase IV is responsible for unlinking DNA following replication. Fluoroquinolone-
gyrase-DNA and fluoroquinolone-topoisomerase IV-DNA lethal complexes are formed and the 
DNA replication is blocked. This leads to bactericid effect therefore bacterial cells die (27, 29).                                 
 
 
Figure 2. DNA replication.  
http://web.virginia.edu/Heidi/chapter30/Images/8883n30_15.jpg 
 
1.3 Mechanisms of resistance against fluoroquinolones 
Until recently, two mechanisms had been found to determine resistance to fluoroquinolones (and 
quinolones, since in almost all cases organisms resistant to fluoroquinolones are resistant to 
nalidixic acid as well) (5). The most important of these mechanisms in Enterobacteriaceae is the 
accumulation of mutations in the bacterial enzymes targeted by fluoroquinolones: DNA gyrase 
and DNA topoisomerase IV (28). Quinolones and fluoroquinolones bind to these enzymes and 
stabilise a drug-enzyme-cleaved DNA complex allowing lethal double-stranded DNA breaks to 
accumulate unrepaired (29). Each target enzyme’s coding gene (namely gyrA, gyrB for DNA 
gyrase and parC, parE for DNA topoisomerase IV) has quinolone-resistance determining regions 
(QRDRs), i.e. portions of the DNA-binding surface of the enzyme (30) at which aminoacid 
substitutions can diminish quinolone binding. Generally, multiple mutations are required to 
achieve clinically important resistance in Enterobacteriaceae; when such organisms are quinolone 
resistant they are nearly always found to have one or more QRDR mutations (Table 1). Another 
well-described resistance mechanism is the decreased intracellular drug accumulation by 
upregulation of native efflux pumps (31) (e.g. AcrAB-TolC in E. coli) and/or decreased 
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expression of outer membrane porins (32). Several Enterobacteriaceae species own a 
chromosomal native AcrAB-TolC efflux pump belonging to the resistance-nodulation division 
(RND) family. AcrA is a membrane fusion protein, AcrB is an inner-membrane pump and TolC 
is an outer-membrane protein and they build up an efflux pump whose overexpression leads to 
high-level fluoroquinolone resistance observed in E. coli and Klebsiella spp. (15, 16, 31). 
Permeability of Gram-negative cell wall to fluoroquinolones was also described, notably rough 
LPS-mutants of Salmonella typhimurium have an MIC 2-4 folds decrement to hydrophobic 
agents like nalidixic acid compared to the smooth LPS-variant, but MICs to hydrophilic (e.g: 
ciprofloxacin and norfloxacin) are not affected (13). In the case of OmpF mutants in E. coli a 
two-fold increase in the MIC of nalidixic acid, norfloxacin and ciprofloxacin was observed in the 
range of low-level resistance (13, 14). 
These mechanisms of resistance are mutational, arising in an individual organism and then 
passing vertically to its surviving progeny. Neither of the above mentioned mechanism seems to 
transfer effectively on mobile genetic elements (5). 
 
Table 1. MIC values with aminoacid substitutions due to mutations in gyrA, gyrB and parC. 
Strain Ciprofloxacin MIC 
(µg/ml) 
gyrA gyrB parC 
C20 0.007 Ser83… Asp87 Lys447 Ser80…Glu84 
C1 0.06 Ser83… Asp87 Lys447 Ser80…Glu84 
C8 0.125 Ser83… Asp87 Lys447 Ser80…Glu84 
C5 0.25 Ser83… Asp87 Lys447 Ser80…Glu84 
C4 0.25 Leu83…Asp87 Lys447 Ser80…Glu84 
C10 1 Leu83…Asp87 Lys447 Arg80…Glu84 
1327 2 Leu83…Asp87 Lys447 Ile80…Val84 
1289 4 Leu83…Asp87 Lys447 Arg80…Glu84 
1363 4 Leu83…Asp87 Glu447 Ser80…Lys84 
1273 8 Leu83…Tyr87 Lys447 Ser80…Lys84 
1331 8 Leu83…Asn87 Lys447 Ser80…Lys84 
1574 8 Leu83…Asn87 Lys447 Ile80…Glu84 
1283 16 Leu83…Asn87 Lys447 Arg80…Glu84 
1334 16 Leu83…Asn87 Lys447 Ile80…Glu84 
1360 32 Leu83…Tyr87 Lys447 Ser80…Lys84 
1416 32 Leu83…Asn87 Lys447 Ile80…Glu84 
1323 64 Leu83…Asn87 Lys447 Ile80…Glu84 
1319 64 Leu83…Asn87 Lys447 Ile80…Val84 
1383 128 Leu83…Tyr87 Lys447 Ile80…Lys84 
 (9) 
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(8) 
 
Figure 3. Distribution of E. coli clinical isolates in susceptible and resistant MIC values.  
 
Internationally-approved resistance breakpoints are required to determine which organism is 
susceptible or resistant. Figure 3 shows the EUCAST distribution in E. coli of different 
ciprofloxacin MIC values, and low-level resistance (from 0.06 µg/ml to 0.5 µg/ml) are also 
highlighted (8). This unique status is below the resistance breakpoint and referres to a 
heterogenous population which does not necessarily have aminoacid substitution in gyrase or 
topoisomerase IV (9) because plasmid-mediated quinolone resistance determinants can maintain 
this phenotype. These determinants increase also the mutation frequency and in case of exposure 
to fluoroquinolones will facilitate the selection of high-level resistance (12). 
 
 
Susceptible Resistant 
Low-level 
resistance 
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1.4 Plasmid-mediated quinolone resistance determinants 
Three different mechanisms were detected, namely Qnr determinants (12), quinolone specific 
efflux pumps (20, 21) and the aminoglycoside acetyltranferase(6’)-Ib-cr variant enzyme (22). The 
genes of these determinants are plasmid localized and individually cause low-level resistance. 
 
1.4.1 Qnr determinants 
The Qnr proteins belong to the pentapeptide-repeat family, which is defined by a tandem five 
aminoacid repeat with the recurrent motif [Ser, Thr, Ala or Val] [Asp or Asn] [Leu or Phe] [Ser, 
Thr or Arg] [Gly] (33). More than 500 proteins are known to contain such pentapeptide-repeat 
motifs, but the function of nearly all of these proteins is unknown (5). 
So far several members of Qnr determinants were identified and labeled as Qnr A, B, S, C and D 
while aminoacid variations are indicated in numbering (Figure 4) (34). Their genes were 
described in human clinical bacterial isolates worldwide (5, 24, 25, 26, 35). The first qnr, now 
named qnrA1 was detected in 1998 from K. pneumoniae (12), and to date 7 different variants of 
qnrA are known (36). In the case of qnrS, the first was found in 2005, in Shigella flexneri 2b (37), 
and until today 5 variants are recognised (36). The most heterogenous cluster of the qnr gene 
family is qnrB, having 47 different alleles (36, 38), the first of them detected in 2006 in K. 
pneumoniae (39). Two additional members of the qnr gene family were detected in 2009, namely 
qnrC in Proteus mirabilis and qnrD in Salmonella enterica Serovar Kentucky and 
Bovismorbificans. Only one allele is known for each of these last two determinants (36, 40, 41). 
Chromosomal qnr genes were also discovered and named after the specific organism where it 
was found and shortened like Vvqnr from Vibrio vulnificans or Efqnr from Enterococcus faecalis 
(34). The progenitor of qnrA gene was discovered in an environmental bacterium Shewanella 
algae, while the source of qnrB determinants was found to be Citrobacter spp. (34, 38). All qnr 
determinants are listed in a homepage: www.lahey.org/qnrStudies and updated regulary after the 
new publications (36). 
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           Figure 4. Family of the qnr determinants with Genbank accession numbers (40). 
 
The direct effect of Qnr A is the reverse of the inhibition of gyrase-mediated DNA supercoiling 
caused by ciprofloxacin. Qnr A binding to gyrase or topoisomerase IV inhibits the gyrase-DNA 
interaction, and could account at least in part for the protection against quinolones by minimising 
opportunities for these agents to stabilise the lethal gyrase-DNA-quinolone complex (5). The first 
qnr-harbouring plasmid (pMG252) had a broad host range feature and could be transferred by 
conjugation from E. coli to C. freundii, S. typhimurium and P. aeruginosa (12). Quinolone 
resistance was expressed in all transconjugant strains with ciprofloxacin MICs showing 2-5 times 
increment at the range of low-level resistance (0.125 µg/mL in C. freundii, 0.25 µg/mL in S. 
typhimurium, 0.5 µg/mL in P. aeruginosa). In all genera, the highest resistance was seen with 
nalidixic acid and the lowest with MICs of clinafloxacin. Mutation frequency increased 100 times 
(from 1.6x10-8 to 3.5x10-6) in J53 E. coli with pMG252 comparing to the one without the plasmid 
(12). 
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The clinical importance and the selection of qnr positive cells to high-level fluoroquinolone 
resistance can be demonstrated by mutant preventive concentration (MPC), the lowest 
concentration at which no mutants can be obtained. Figure 5 shows how an inoculum of 1010 E. 
coli J53 carrying qnr-harbouring plasmid (pMG252) has 1.25 µg/ml MPC value, compared to the 
wild-type E. coli J53 without qnr-harbouring plasmid (pMG252) having less than 0.2 µg/ml MPC 
value. This data explains the mutation window, from 0.2 µg/ml to 1.25 µg/ml, at which during 
ciprofloxacin therapy novel mutations can be promoted. Since with per os administered 
ciprofloxacin the maximum serum concentration reaches 2.9 µg/ml and 35% bounds to serum 
proteins, the remaining ~1.8 µg/ml is free. This free ciprofloxacin will not be able to penetrate 
equally in each tissue, and bacterial cells will be exposed to lower concentrations, giving 
opportunity for qnr positive cells to develop mutation. 
Figure 6 gives similar data comparing an inoculum of 1010 E. coli J53 with one gyrA mutation 
has also 1.25 µg/ml MPC value, compared with E. coli J53 lacking gyrA mutation has less than 
0.2 µg/ml. The two graphs together show that qnr positive and 1-time gyrA mutant bacterial cells 
behave similary after exposure to ciprofloxacin, both can develop new mutation (42). 
 
                  
 
   Figure 5. (42)         Figure 6. (42) 
E. coli J53 with and without pMG252                  E. coli J53 with and without gyrA mutation  
(qnrA1-harbouring plasmid)                                  (Ser83Leu) 
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Further explanation of acquiring chromosomal mutations by qnr determinants is based on the 
induction of SOS response of bacterial cells when DNA damage occurs. LexA is the central 
regulator of the SOS response system, which represses qnrB expression (45). All known qnrB 
determinants have a conservated region in its promoter sequence with a LexA-binding site 
allowing controll (Figure 7). Ciprofloxacin, a known inducer of SOS response, upregulates LexA 
which deliberates qnrB from the repression and enhances its RNA and protein synthesis (Figure 
8). The regulation of other qnr determinants is not known (38, 44, 45). 
 
 
LexA-binding site                                    
 
 
qnrB1 ATGACGCCATTACTGTATAAAAAAACAGGTACAA--AT-ATGGCTCTGGC DQ351241 
qnrB2 ATGACGCCATTACTGTATAAAAAAACAGGTACAA-AAT-ATGGCTCTGGC DQ351242 
qnrB3 ATGACGCCATTACTGTATAAAAAAACAGGTACAA--AT-ATGGCTCTGGC DQ303920 
qntB4 ATGTTGCAATCACTGTATAAAAAAACAGGT-TAATCATGATGACTCTGGC DQ303921 
qnrB5 ATGACGCCATTACTGTATAAAAACACAGGCATAG--AT-ATGACTCTGGC DQ303919 
 
Promoter sequence                                        qnrB gene 
 
 
 
 
 
 
Figure 7. Promoter region of each qnrB determinant starts with ATG triplet and has conservative 
motifs CTGT and ACAG acting as LexA binding site. This part explains the role of qnrB 
determinants in SOS response. The qnrB gene coding sequence starts at the second ATG triplet, 
encoding for methionin (44). 
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Before exposure  
 
 
 
 
 
 
 
 
After exposure 
 
 
 
 
 
 
 
 
Figure 8. SOS response is activated after DNA damage. Exposure to ciprofloxacin can induce 
SOS response leading to the deliberation of qnrB gene expression from LexA repression. This 
promotes RNA and protein synthesis of Qnr B determinant (45). 
 
 
 
 
 
 
 
 
 
 
qnrB 
qnrB 
RNA 
QNR B  
Protein synthesis 
Repression by LexA 
RNA 
Deliberation 
from LexA  
Exposure to ciprofloxacin  
Promoter sequence 
Promoter sequence 
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1.4.2 Fluoroquinolone specific efflux pumps 
QepA and QepA2 are 511-aminoacid proteins related to the major facilitator superfamily (MFS) 
of 14-transmembrane segment efflux pumps (Figure 9). Both cause a moderate increase (five or 
more times) in the range of low-level resistance to norfloxacin and ciprofloxacin, but do not 
significantly affect activity of less hydrophilic (levofloxacin, moxifloxacin, pefloxacin, 
gatifloxacin, sparfloxacin) or hydrophobic (nalidixic acid) derivatives. Its function is an active 
efflux, the energy is provided by a proton motive force and inhibited by carbonyl cyanide m-
chlorophenylhydrazone (20, 46, 47). It was first described in Japan, in 2007 on a plasmid of a 
clinical urine isolate of E. coli. Other surveys from Belgium, France and China reported this 
determinant (20, 24, 35, 47, 48). 
 
 
                     
        
 
Figure 9. The secondary transmembrane structure of QepA (511-aminoacid protein) (20). 
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The OqxAB (Figure 10) belongs to the resistance-nodulation division (RND) family, being one 
of the first plasmid-borne efflux pumps described. The oqxA gene codes for the OqxA membrane 
fusion protein while the oqxB codes for the OqxB protein containing 12-transmemrbane α-helices 
for the inner-membrane pump. This system requires TolC outer-membrane protein to function 
fully (21). This is the first identified genetic resistance mechanism towards olaquindox, an agent 
used as growth enhancer in pigs (21). Later on other substrates of this pump were detected such 
as: chloramphenicol (21), nalidix acid, norfloxacin and ciprofloxacin (49). The oqxAB was first 
detected in 2004 in porcine isolates in Denmark and Sweden, on a plasmid of E. coli (21). In 
2009 a report from the Republic of Korea detected in human clinical isolates, located on a 
plasmid of E. coli and in the chromosome of K. pneumoniae. In 2010 in a survey of farmworkers 
in China revealed this dererminant in E. coli. (35, 50). Inhibitor of this efflux pump carbonyl 
cyanide m-chlorophenylhydrazone (21). 
 
 
                                
Figure 10. Structure of OqxAB efflux pump as a RND type efflux pump.   
         http://www.mpexpharma.com/images/illustration.gif  
 
 
 
 
 
 
oqxB  inner membrane pump 
 
oqxA membrane fusion protesin 
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1.4.3 Aminoglycoside acetyltranferase(6’)-Ib-cr variant 
Approximately 30 variants of aminoglycoside acetyltransferase(6’)-Ib have already been 
described since 1986. Two codon changes, namely Trp102Arg and Asp179Tyr, are found to be 
necessary, sufficient and unique for the cr-variant (ciprofloxacin resistance phenotype) comparing 
to the wild-type aminoglycoside acetyltransferase(6’)-Ib (22). The function of the enzyme is to 
N-acetylate ciprofloxacin at the amino nitrogen on its piperazinyl substituent (Figure 11) (22). 
Norfloxacin has also free amino nitrogen acting as substrate of enzyme, while other 
fluoroquinolones lacking an unsubstituted piperazinyl nitrogen, like levofloxacin and moxiflxacin 
are unaffected (5). The effectiveness of this enzyme is modest, leading to an increase in the MIC 
of ciprofloxacin and norfloxacin three-fold to four-fold in the range of low-level resistance (22). 
 
 
 
                   N-acetylation           
ciprofloxacin                        N-acetyl ciprofloxacin  
 
 
Figure 11. Action of aac(6’)-Ib-cr variant enzyme on ciprofloxacin: N-acetylation of amino 
nitrogen on the piperazinyl substituent (5). 
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Although the activity of the aac(6’)-Ib-cr variant enzyme is modest, it increases the mutant 
preventive concentration (MPC) of the host cell to 3.2 µg/mL thus facilitating the selection of 
high-level fluoroquinolone resistance. Figure 12 shows the ciprofloxacin values where aac(6’)-
Ib-cr positive isolates have opportunity to develop new mutations in quinolone-resistance 
determining region (QRDR). During per os ciprofloxacin therapy the peak free serum 
ciprofloxacin concentration is approximately 1.8 µg/mL, it will not reach MPC value. 
Furthermore, the qnr and aac(6’)-Ib-cr variant work additively, since these two determinants 
have different mechanism of action and they together enhance the development of 
fluoroquinolone resistance (22). 
 
 
 
 
Figure 12. Mutant preventive concentration (MPC) assay for comparing wild-type E. coli J53  
with E. coli J53 carring pBCSK-aac(6')-Ib-cr . The graph shows that, at 1.6 µg/ml the peak 
serum ciprofloxacin concentration surviving mutants could be still recovered. The presence of 
aac(6')-Ib-cr increased the mutant preventive concentration from 0.2 µg/ml to 3.2 µg/ml (22). 
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2. Aim of the thesis 
 
The aim of this thesis was to investigate the plasmid-mediated quinolone resistance determinants. 
For this purpose we collected clinical Enterobactericaeae isolates from microbiological 
diagnostic laboratories of North-East Italy. We focused on low-level and high-level 
fluoroquinolone resistant strains, plus those exhibiting beta-lactam-resistant phenotypes. 
Our objectives were: 
1) to screen for genes of plasmid-mediated quinolone resistance (PMQR) determinants by 
polymerase chain reaction (PCR) and sequencing, and to detect their prevalence and 
distribution in the collection 
 
2) to assess the ciprofloxacin and levofloxacin MIC distributions among PMQR-positive 
strains  
 
3) to check PMQR-positive strains for beta-lactamase genes by PCR and sequencing 
 
4) to investigate the PMQR-harbouring plasmids by Southern blot to identify the plasmidic 
localization of PMQR-genes or by conjugation to analyse the transferability of plasmids 
or by PCR-based replicon typing to detect the genes of autonomus plasmid replication or 
by plasmid DNA sequencing 
 
5) to characterize the clonal relationship of PMQR-positive strains by pulsed-field 
gelelectrophoresis or random-amplified polymorphic DNA or multilocus sequence typing 
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3. Materials and methods 
 
3.1 Strain collection: 756 Enterobacteriaceae strains were collected from the Microbiology 
diagnostic laboratory of Bolzano Central Hospital, Ospedale „Santa Maria del Carmine” of 
Rovereto, Ospedale „Santa S. Chiara” of Trento, Policlinico GB Rossi of Verona and Ospedale 
„S. Bortolo” of Vicenza. All the isolates included in the study were from specimens from 
inpatients admitted at hospitals or long-term care facilities, and from outpatients. Collection of 
nonreplicate Enterobacteriaceae isolates was carried out during three days a week, for a total 
period of six months, according to the following criteria: i) all isolates exhibiting an intermediate 
or resistance phenotype to ciprofloxacin and/or levofloxacin; ii) all isolates suspected/confirmed 
for extended-spectrum beta-lactamases (ESBLs) production; iii) all isolates, regardless of their 
resistance phenotype (during one of the three days of collection). 
 
3.2 Minimal Inhibitory Concentration (MIC) for ciprofloxacin and levofloxacin by broth 
microdilution method. 
Ciprofloxacin and levofloxacin MICs were measured in microdilution plates with a final volume 
of 200 µl/well. 100 µl Mueller Hinton broth was put in each well adding an extra 74.4 µl only in 
the first well and 25.6 µl ciprofloxacin from a 2 mg/ml mother solution. Serial dilution was 
carried out and 100 µl of bacterial inoculum with 105 cfu/ml was added in each well, obtaining 
ciprofloxacin concentration of 128 µg/ml in the first well and 0.06 µg/ml in the last. In case of the 
levofloxacin 10.24 µl was added in the first well from a 5 mg/ml mother solution. After serial 
dilution and the addition of bacterial inoculum with 105 cfu/ml in each well levofloxacin 
concentrations of 128 µg/ml in the first and 0.06 µg/ml in the last were obtained. 
 
3.3 Screening by PCR for qnr, aac(6’)-Ib-cr variant, qepA, oqxAB and beta-lactamase genes 
Colonies of each Enterobacteriaceae strain were transferred to 500 µl distilled water in Eppendorf 
tubes, boiled at 100°C for 15 minutes and centrifuged at 13000 rpm for 10 minutes. 3 µl of the 
supernatant was used to prepare 200 ng of DNA templates, 1.25 U Taq DNA polymerase, 0.5 µM 
of each primer, 0.2 mM dNTP mix, 2.5 mM Buffer with Mg2+ filled up with distillated water for 
a total volume of 50 µl PCR reaction. Positive (containing strains with known qnr genes) and 
negative (without DNA template) controls were included in each run. DNA fragments were 
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analyzed by electrophoresis in a 0.8% agarose gel at 100 V for 45 min in 1x TAE [40 mM Tris–
HCl (pH 8.3), 2 mM acetate and 1 mM EDTA] and stained with 0.05 mg/L ethidium bromide 
solution (51). 
All the primers used in the screen are listed in Table 2. Multiplex PCR of qnrA, qnrB and qnrS 
genes was performed with qnrA Fwd and qnrA Rev to give a 516 bp product; with qnrB Fwd and 
qnrB Rev to give a 469 bp product; with qnrS Fwd and qnrS Rev to give a 417 bp product. The 
PCR conditions were 94°C for 45 s, 53°C for 45 s, and 72°C for 60 s for 32 cycles and a final 
elongation at 72°C for 10 min (52). Screening was carried out by PCR for qnrC gene using 
primers qnrC Fwd and qnrC Rev with PCR conditions 94°C for 30 s, 50°C for 30 s, 72°C for 30 s 
for 30 cycles and a final extension at 72°C for 10 minutes to obtain a 447 bp product (41). 
Screening for qnrD gene was performed with primers qnrD Fwd and qnrD Rev with PCR 
conditions 94°C for 1 min, 50 °C for 1 min for 72°C for 1 min for 30 cycles and a final extension 
at 72°C for 10 min for 644 bp PCR product (40). 
Aac(6’)-Ib was amplified by PCR with primers aac(6’)-Ib Fwd and aac(6’)-Ib Rev to produce a 
482 bp product. Primers were chosen to amplify all known aac(6’)-Ib variants. PCR conditions 
were 94°C for 45 s, 55°C for 45 s, and 72°C for 45 s for 34 cycles and a final elongation at 72°C 
for 10 min (53). 
A 199 bp fragment of qepA gene was amplified by PCR with primers qepA Fwd and qepA Rev. 
The PCR conditions were: denaturation at 96°C for 1 min, annealing at 60°C for 1 min, and 
extension at 72°C for 1 min for 30 cycles a final step was at 72°C for 5 min (54). Screening by 
PCR for OqxAB efflux pump was performed, to amplify oqxA gene of membrane fusion protein 
with primers oqxA Fwd and oqxA Rev with thermal profile for 34 cycles of 94oC for 45 s, 57oC 
for 45 s, 68oC for 60 s was used to obtain 392 bp PCR product. To amplify oqxB gene of inner-
membrane pump, oqxB Fwd and oqxB Rev set of primer was used with PCR conditions as 
follows: 94oC for 45 s, 64oC for 45 s and 72oC for 60 s for 32 cycles to obtain 512 bp PCR 
product (50). 
PMQR positive strains were screened for genes of SHV, TEM, CTX-M, VIM, IMP, OXA and 
LAP beta-lactamases with primers listed in Table 2. SHV PCR reaction was performed with 1 
min denaturation at 94°C, 1 min annealing at 56 °C 1 min elongation at 72°C for 30 cycles and a 
final elongation at 72°C for 10 min, obtaining a PCR product of 930 bp (55). 
TEM PCR was performed for product of 867 bp as follows: 94°C for 1 min, 58°C for 1 min, 
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72°C for 1 min for 30 cycles and a final elongation at 72°C for 10 min (55). 
CTX-M-1 group PCR was carried out with CTX-M-1 Fwd and CTX-M-1 Rev primers 
denaturation at 94°C for 1 min, annealing at 62°C for 1 min, elongation at 72°C for 1 min for 35 
cycles, with a final elongation 72°C for 10 min for a 688 bp PCR product (56). 
CTX-M-9 group PCR was carried out with CTX-M-9 Fwd and CTX-M-9 Rev primers 
denaturation at 94°C for 1 min, annealing at 62°C for 1 min, elongation at 72°C for 1 min for 35 
cycles, with a final elongation at 72°C for 10 min 561 bp PCR product (56). 
VIM PCR was carried out with VIM Fwd and VIM Rev primers, initial denaturation at 94°C for 
10 min and 30 cyles of 94°C for 40 s, 55°C for 40 s and 72°C for 1 min and one cycle of final 
elongation at 72°C for 10 min obtaining 390 bp product (56). 
IMP PCR was performed with IMP Fwd and IMP Rev set of primers with initial denaturation at 
94°C for 10 min and 30 cyles of 94°C for 40 s, 55°C for 40 s and 72°C for 1 min and one cycle of 
final elongation at 72°C for 10 min obtaining 139 bp PCR product (56). 
OXA beta-lactamase genes were screened with OXA Fwd and Rev set of primers with a thermal 
profile of initial denaturation at 94°C for 10 min and 30 cyles of 94°C for 40 s, 60°C for 40 s and 
72°C for 1 min and one cycle of final elongation at 72°C for 10 min to obtain 564 bp PCR 
product (56). LAP Fwd and LAP Rev set of primers were used to amplify blaLAP gene with a 
thermal profile of 3 min at 93°C and 40 cycles of 1 min at 93°C, 1 min at 55°C, and 1 min at 
72°C and, finally, 7 min at 72°C for 858 bp PCR product (57). 
 
3.4 Sequencing of PCR products and analysis by NCBI Genebank database  
Positive PCR products were purified by QIAquick PCR Purification Kit (Qiagen) and sent to be 
sequenced on both strands to Eurofins MWG Operon, Germany. Sequence analysis was 
performed with Blast program of NCBI Genebank database http://blast.ncbi.nlm.nih.gov/ . 
 
3.5 Cloning of qnr and aac(6’)-Ib-cr genes in plasmid vector 
Positive PCR products of qnr and aac(6’)-Ib-cr genes were purified by QIAquick PCR 
Purification Kit (Qiagen) and ligated in plasmid vector from Perfect PCR cloing kit (5Prime). 
Ligation reaction was performed at 4°C for 1 hour in a total volume of 10 µl, including 500 ng 
pPrime cloning vector, 100 ng of insertion PCR product, 1x Ligation mastermix and RNase free 
water. After the reaction, ligation enzyme was inactivated at 70°C for 10 min. 
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3.6 Transformation of DH5 alpha E. coli cells by heat shock 
100 µl DH5 alpha cells and 10 µl ligation reaction were transfered to a falcon tube and kept on 
ice for 30 min. Heat pulse was performed at 42°C for not more the 40 sec. The shocked cells 
were incubated in SOC medium (triptone 2% w/v, yeast extract 0.5% w/v and salt solution 10% 
v/v [6 g NaCl, 1.87 g KCl, 20.33 g MgCl2, 24.65 g MgSO4 and 36 g glucose for 1 liter]) for 5 
hours at 37°C. 80 µl of inoculums was plated on 20 ml Luria-Bertani agar (yeast extract 0.5% 
w/v, triptone 1% w/v, NaCl 1% w/v, 1.5% w/v agar) plates containing 100 µg/ml ampicillin for 
an overnight incubation at 37°C. 
 
3.7 Incompatibility grouping of plasmids by PCR-based replicon typing  
PCR-based replicon typing (PBRT) was performed in 50 µl of PCR reaction, using specific 
primers to detect inc types of plasmids. Five multiplex PCR reactions were applied, 1. multiplex 
PCR: HI 1 Fwd and Rev, HI2 Fwd and Rev, I1 Fwd and Rev, 2. multiplex PCR: X Fwd and Rev, 
L/M Fwd and Rev, N Fwd and Rev, 3. multiplex PCR: FIA Fwd and Rev, FIB Fwd and Rev, W 
Fwd and Rev, 4. multiplex PCR: Y Fwd and Rev, P Fwd and Rev, FIC Fwd and Rev, 5. muliplex 
PCR: A/C Fwd and Rev, T Fwd and Rev, FIIS Fwd and Rev. Seven simplex PCR reactions were 
included namely: 1. FrepB Fwd and Rev, 2. K/B Fwd and K Rev, 3. K/B Fwd and B Rev, 4. Q 
Fwd and Rev, 5. U Fwd and Rev, 6. R Fwd and Rev, 7. ColE Fwd and Rev (Table 2). For each 
reaction 1.25 U Taq DNA polymerase, 0.5 µM of each primer, 0.2 mM dNTP mix, 2.5 mM 
Buffer with Mg2+ 200 ng DNA prepared from each qnr and aac(6’)-Ib-cr positive strain, filled up 
with distilled water for a total volume of 50 µl PCR reaction. Thermal profile of replicon typing 
for all the multiplex PCR reactions and simplex PCR 2, 3, 5, 6, 7 was as follows: initial 
denaturation at 94oC for 5 min, and 30 cycles of 94oC for 1 min, 60oC for 30 sec, 72oC for 1 min 
and final elongation at 72oC for 5 min. Simplex PCR 1. was used with annealing at 52 oC, and 
Simplex PCR 4. with annealing at 62 oC (58, 59, 60). 
 
3.8 Conjugation of qnr positive plasmids was performed. Each qnr positive strain was plasmid 
donor and J53 AzidR E.coli was used as recipient cell. Each strain’s inoculum reached 0.6 OD640, 
measured by spectrophotometer (T60 UV-Visible Spectrophotometer, PG Instruments) when 
they were applied in reaction (500 µl of donor inoculum, 500 µl of recipient inoculum in total of 
5 ml Luria-Bertani broth). The reaction tubes were incubated at 37 ºC for 5 hours.  
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Transconjugant cells were selected on Luria-Bertani agar plates containing 100 µg/ml sodium-
azid combined with either 16 µg/ml nalidixic acid or 10 µg/ml ceftazidime. Transconjugant cells 
were analyzed by PCR for the presence of the qnr genes and MIC values of the transconjugant 
cells were measured by microdilution method for nalidixic acid, ciprofloxacin and levofloxacin. 
 
3.9 Plasmid extraction and detection: plasmid extraction was carried out by commercial kit 
(Qiagen) from an overnight incubation of 5 ml Luria-Bertani broth of each qnr positive strain. 
The plasmid extractions were loaded in a 0.4% (w/v) agargel and runned at 60 V for 60 min. The 
gel was stained with 1x Gel Red solution (Biotum). 
 
3.10 Southern blot 
Plasmid extractions from each qnr positive strain were treated with Plasmid-safe ATP-dependent 
DNase (Epicenter). Both untreated and treated plasmids were loaded on a 0.4% (w/v) agargel and 
separated by electrophoretion on 60 V for 60 min. The plasmids in the gel were denaturated for 
30 min in denaturation buffer [0.5 M NaOH, 1.5 M NaCl] and neutralized in neutralizing buffer 
[pH 7, 0.5 M Tris-HCl, 1.5 M NaCl], transferred onto the surface of a nylon membrane by 
overnight blotting in transfer buffer 20xSSC (pH 7, 3 M NaCl, 0.3 M Na3C6H5O7 x 2H2O). The 
denaturated transferred plasmids were dried in the membrane by heating on 80oC for 2 hours. 
Specific qnr probes incorporating digoxigenin-11-dUTP (Roche, Mannheim, Germany) were 
performed by PCR. After denaturating the probe on 100 oC for 15 min, hybridization was carried 
out on 44.6 oC for 16 hours. Detection was carried out by developing chemiluminescens detection 
film (Roche, Mannheim, Germany) in development and fixation buffers (Sigma). 
 
3.11 Inverse PCR of qnrD-harbouring plasmids  
PCR reaction was carried out on the plasmid extraction of qnrD positive strains. The 
complementar antiparalelle strand of qnrD Fwd and qnrD Rev primers named as INVDF/Rev and 
INVDR/Fwd, respectively (listed in Table 2) were used with the following thermal profile: initial 
denaturation at 95oC for 2 min, 30 cycles of 94 oC for 30 sec, 53 oC for 30 sec, 72 oC for 3 min 
with a final elongation of 72 oC for 10 min to obtain 2200 bp PCR product. Sequencing of 
positive PCR product was carried out (Eurofins MWG Operon, Germany) and based on the DNA 
sequence four additional primers were designed, namely Pl 1 Rev, Pl 2 Fwd, Pl 3 Fwd and Pl 4 
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Rev (Table 2, Figure 16) by tools of Eurofins MWG Operon, Germany. These primers were 
used with the same thermal profile to amplify 994 bp PCR product with Pl1 Fwd and Pl2 Rev, 
while 710 bp with Pl3 Fwd and qnrD Rev and 972 bp with qnrD Fwd and Pl4 Rev. Positive PCR 
products were purified by QIAquick PCR Purification Kit (Qiagen) and sequenced by Eurofins 
MWG Operon, Germany. 
 
3.12 PCR and sequencing of quinolone-resistance determining regions of qnrD positive isolates  
Quinolone-resistance determining regions of four qnrD positive Proteus mirabilis strains were 
amplified in PCR reactions, with 1 unit Taq polymerase, 45 mM KCl, 2.5 mM Mg++, 200 µM 
each dNTPs, 0.5 µM each primer, 3 µl DNA from boiled colony. 538 bp PCR product with gyrA 
Pro Fwd and gyrA Pro Rev, 535 bp with gyrB Pro Fwd and gyrB Pro Rev, 351 bp parC Pro Fwd 
and parC Pro Rev, 460 bp with parE Pro Fwd and parE Pro Rev were obtained (Primers listed in 
Table 2) The PCR reaction was performed for gyrA with initial denaturation at 94oC for 5 min, 
followed by 35 cycles of denaturation at 95oC for 45s, annealing at 52oC for 20 s, elongation at 
72oC for 30s and final elongation at 72oC for 10 min. The same PCR reaction was used with 
annealing at 54oC for gyrB, at 52oC for parC and at 56oC for parE (61). Positive PCR products 
were sequenced by Eurofins MWG Operon and analyzed by Blast program of NCBI Genbank. 
 
3.13 Pulsed-field gelelectrophoresis (PFGE)  
5 ml Luria-Bertani broth overnight incubation of each qnrS positive strain. 500 microliter 
inoculum to spin down at 8000 rpm for 5 min. Pellet resuspended in 500 microliter TE buffer (10 
mM Tris-HCl pH 7.5, 1 mM Edta pH 8). Mixed with 500 microliter 2 % (w/v) low-melting 
agarose (BioRad). Pipet the plugs in frame (BioRad). Solidified at room temperature for 15 min. 
Plugs washed in 5 ml of lysis buffer [6 mM Tris-HCl pH 8, 100 mM Edta pH 8, 1 M NaCl, 1% 
Brij, 0.4 % deoxycolat, 1 % sarkozyl, 0.1 % w/v lyzozim] at 37 oC overnight. Plugs washed in 5 
ml of proteinase K buffer [0.5 M Edta pH 8, 1 % w/v sarkozyl, 0.005 % w/v proteinase K] at 50 
oC overnight. Plugs washed in 20 ml of TE buffer [Tris-HCl 10 mM pH 7.5, EDTA 1 mM pH 8] 
5 times at room temperature. 30 U Xba I digestion overnight and run in CHEF DRTM 
Electrophoresis carried out with BioRad 6V/cm, 120o angel, initial switch time 2 s and final 
switch time 30 s for 21 hours run. 
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3.14 Multilocus sequence typing (MLST) for K. pneumoniae 
Seven housekeeping genes rpoB, gapA, mdh, pgi, phoE, infB, tonB were amplified with specific 
primers (listed in Table 2). PCR reaction in total volume of 50 µl including 1 unit Taq 
polymerase, 45 mM KCl, 2.5 mM Mg++, 200 µM each dNTPs, 0.5 µM each primer, 3 µl DNA 
from boiled colony. 501 bp PCR product with rpoB Fwd and Rev, 450 bp with gapA Fwd and 
Rev, 477 bp with mdh Fwd and Rev, 432 bp pgi Fwd and Rev, 420 bp pho Fwd and Rev, 318 bp 
infB Fwd and Rev, 414 bp tonb Fwd and Rev were amplified. PCR thermal profile was used with 
initial denaturation at 95oC for 5 min, and 35 cycles of 95oC for 1 min, 50oC for 1 min and 72oC 
for 1 min with final elongation 72oC for 10 min. Exception was gapA used with 60oC and tonB 
with 45oC of annealing. Positive PCR products were sequenced and allelic numbers were 
obtained after the alignament of sequences of these seven housekeeping genes at the following 
homepage http://www.pasteur.fr/recherche/genopole/PF8/mlst/Kpneumoniae (62). 
 
3.15 Random amplified polymorhic DNA (RAPD) 
Three single primers were used in separate PCR reations, namely OPA 11, OPX13 and OPZ08 
(Table 2) to obtain polymorphic bands for the four qnrD positive Proteus mirabilis strains. PCR 
reaction was performed in total volume of 50 µl including 1 unit Taq polymeras, 45 mM KCl, 2.5 
mM Mg++, 200 µM, each dNTPs, 4 µM primer, 3 µl DNA from boiled colony. PCR cycling 
thermal profile was 92oC for 4 min, 40 cycles of denaturation at 94oC for 1 min, annealing at 
40oC for 1 min and elonagation at 72 oC for 5 min, and a final elongation at 72 oC for 5 min. The 
obtained PCR products were run in 1.5% agarose gel and stained with 1x GelRed (Biotum) (63). 
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Table 2. Primers used in the study 
 
Primers for screening of PMQR and beta-lactamase genes Primers for plasmid replicon typing 
Primer name Ref. Primer sequence Primer name Ref. Primer sequence 
qnrA Fwd 51 5-ATTTCTCACGCCAGGATTTG-3 HI 1 Fwd 58 5-ggagcgatggattacttcagtac-3 
qnrA Rev 51 5-GATCGGCAAAGGTTAGGTCA-3 HI 1 Rev 58 5-tgccgtttcacctcgtgagta-3 
qnrB Fwd 51 5-GATCGTGAAAGCCAGAAAGG-3 HI 2 Fwd 58 5-tttctcctgagtcacctgttaacac-3 
qnrB Rev 51 5-ACGATGCCTGGTAGTTGTCC-3 HI 2 Rev 58 5-ggctcactaccgttgtcatcct-3 
qnrB FQ 1 30 5-ATGACGCCATTACTGTATAA-3 I1 Fwd 58 5-cgaaagccggacggcagaa-3 
qnrB FQ 2 30 5-GATCGCAATGTGTGAAGTTT-3 I1 Rev 58 5-tcgtcgttccgccaagttcgt-3 
qnrS Fwd 51 5-ACGACATTCGTCAACTGCAA-3 X Fwd 58 5-aaccttagaggctatttaagttgctgat-3 
qnrS Rev 51 5-TAAATTGGCACCCTGTAGGC-3 X Rev 58 5-tgagagtcaatttttatctcatgttttagc-3 
qnrC Fwd 41 5-GGGTTGTACATTTATTGAATC-3 L/M Fwd 58 5-ggatgaaaactatcagcatctgaag-3 
qnrC Rev 41 5-TCCACTTTACGAGGTTCT-3 L/M Rev 58 5-ctgcaggggcgattctttagg-3 
qnrD Fwd 40 5-CGAGATCAATTTACGGGGAATA-3 N Fwd 58 5-gtctaacgagcttaccgaag-3 
qnrD Rev 40 5-AACAAGCTGAAGCGCCTG-3 N Rev 58 5-gtttcaactctgccaagttc-3 
aac(6’)-Ib Fwd 53 5-TTGCGATGCTCTATGAGTGGCTA-3 FIA Fwd 58 5-ccatgctggttctagagaaggtg-3 
aac(6’)-Ib Rev 53 5-CTCGAATGCCTGGCGTGTTT-3 FIA Rev 58 5-gtatatccttactggcttccgcag-3 
qepA Fwd 54 5-GCAGGTCCAGCAGCGGGTAG-3 FIB Fwd 58 5-ggagttctgacacacgattttctg-3 
qepA Rev 54 5-CTTCCTGCCCGAGTATCGTG-3 FIB Rev 58 5-ctcccgtcgcttcagggcatt-3 
oqxA Fwd 50 5-CTCGGCGCGATGATGCT-3 W Fwd 58 5-cctaagaacaacaaagcccccg-3 
oqxA Rev 50 5-CCACTCTTCACGGGAGACGA-3 W Rev 58 5-ggtgcgcggcatagaaccgt-3 
oqxB Fwd 50 5- TTCTCCCCCGGCGGGAAGTAC-3 Y Fwd 58 5-aattcaaacaacactgtgcagcctg-3 
oqxB Rev 50 5- CTCGGCCATTTTGGCGCGTA-3 Y Rev 58 5-gcgagaatggacgattacaaaacttt-3 
SHV Fwd 55 5-GGGTTATTCTTATTTGTCGC-3 P Fwd 58 5-ctatggccctgcaaacgcgccagaaa-3 
SHV Rev 55 5-TTAGCGTTGCCAGTGGTC-3 P Rev 58 5-tcacgcgccagggcgcagcc-3 
TEM Fwd 55 5-ATGAGTATTCAACATTTCCG-3 FIC Fwd 58 5-gtgaactggcagatgaggaagg-3 
TEM Rev 55 5-CTGACAGTTACCAATGCTTA-3 FIC Rev 58 5-ttctcctcgtcgccaaactagat-3 
CTX-M-1 Fwd 56 5-TCCCGACGGCTTTCCGCCTT-3 A/C Fwd 58 5-gagaaccaaagacaaagacctgga-3 
CTX-M-1 Rev 56 5-ATGGTTAAAAAATCACTGCGCC-3 A/C Rev 58 5-acgacaaacctgaattgcctcctt-3 
CTX-M-9 Fwd 56 5-GTGACAAAGAGAGTGCAACGG-3 T Fwd 58 5-ttggcctgtttgtgcctaaaccat-3 
CTX-M-9 Rev 56 5-ATGATTCTCGCCGCTGAAGCC-3 T Rev 58 5-cgttgattacacttagctttggac-3 
VIM Fwd 56 5-GATGGTGTTTGGTCGCATA-3 FIIS Fwd 58 5-ctgtcgtaagctgatggc-3 
VIM Rev 56 5-CGAATGCGCAGCACCAG-3 FIIS Rev 58 5-ctctgccacaaacttcagc-3 
IMP Fwd 56 5-TTGACACTCCATTTACDG-3 FrepB Fwd 58 5-tgatcgtttaaggaattttg-3 
IMP Rev 56 5-GATYGAGAATTAAGCCACYCT-3 FrepB Rev 58 5-gaagatcagtcacaccatcc-3 
OXA Fwd 56 5-ggcaccagattcaactttcaag-3 K/B Fwd 58 5-gcggtccggaaagccagaaaac-3 
OXA Rev 56 5-gaccccaagtttcctgtaagtg-3 K Rev 58 5-tctttcacgagcccgccaaa-3 
LAP  Fwd 57 5-CAATACAAAGCACAGAAGACC-3 B Rev 58 5-tctgcgttccgccaagttcga-3 
LAP  Rev 57 5-CCGATCCCTGCAATATGCTC-3 Q Fwd 59 5-tcgtggtcgcgttcaagg tacg-3 
Primers to amplify QRDR of Proteus mirabilis  Q Rev 59 5-ctg taa gtc gat gat ctg ggcgtt-3 
gyrA Pro Fwd This study 5-TGCCAGAGAAATCACACCAG-3 R Fwd 60 5-tcg ctt cat tcc tgc ttc agc-3 
gyrA Pro Rev This study 5-TTTCCAAATCCGCCAGCAG-3 R Rev 60 5-gtg tgc tgt ggt tat gcc tca -3 
gyrB Pro Fwd 61 5- TGA(C/T)GATGC(G/C/A)CG(T/C)GAAGG-3 U Fwd  60 5-tca cga cac aag cgc aag gg-3 
gyrB Pro Rev 61 5- CGTACG(A/G)ATGTG(C/A)GA(G/A)CC-3 U Rev 60 5- tca tgg tac atc tgg gcgc-3 
parC Pro Fwd 61 5- TTGCC(A/T)TTTAT(C/T)GG(G/T)GATGG-3 Col E Fwd 60 5-gtt cgt gca tac agt cca-3 
parC Pro Rev 61 5- CGCGC(A/T)GGCAGCATTTT(A/T)GG-3 Col E Rev 60 5-ggc gaa acc cga cag gac t-3 
parE Pro Fwd 61 5- GCA(G/A)GA(T/G)(C/G)CGCA(G/A)TT(T/C)G-3   
 
parE Pro Rev 61 5-ATC(A/C/G)GAGTC(C/T/G)GCATCCG-3   
 
Primers for multilocus sequence typing Primers for random amplified polymoprhic DNA 
Primer name Ref. Primer sequence Primer name Ref. Primer sequence 
rpoB Fwd 62 5-GGCGAAATGGCWGAGAACCA-3 OPA 11 63 5-caatcgccgt-3 
rpoB Rev 62 5-GAGTCTTCGAAGTTGTAACC-3 OPX 13 63 5-acgggagcaa-3 
gapA Fwd 62 5-TGAAATATGACTCCACTCACGG-3 OPZ 08 63 5-gggtgggtaa-3 
gapA Rev 62 5-CTTCAGAAGCGGCTTTGATGGCTT-3 Primers for qnrD-plasmid sequencing 
mdh Fwd 62 5-CCCAACTCGCTTCAGGTTCAG-3 INVDR/Fwd This study 5-CAGGCGCTTCAGCTTGTT-3 
mdh Rev 62 5-CCG TTTTTCCCCAGCAGCAG-3 INVDF/Rev This study 5-TATTCCCCGTAAATTGATCTCG-3 
pgi Fwd 62 5-GAGAAAAACCTGCCTGTACTGCTGGC-3 Pl1 Rev This study 5-GCCGAAGAAAATAGCCAGAG-3 
pgi Rev 62 5-CGCGCCACGCTTTATAGCGGTTAAT-3 Pl2 Fwd This study 5- TGCTAAGATTGGATTGCGAC-3 
phoE Fwd 62 5-ACCTACCGCAACACCGACTTCTTCGG-3 Pl3 Fwd This study 5-TAATGGGGATGAACGGGAG-3 
phoE Rev 62 5-TGATCAGAACTGGTAGGTGAT-3 Pl4 Rev This study 5-TCGCAATCCAATCTTAGCAAC-3 
infB Fwd 62 5-CTCGCTGCTGGACTATATTCG-3   
 
infB Rev 62 5-CGCTTTCAGCTCAAGAACTTC-3 Primers used to amplify qnrS1 and blaLAP genetic context 
tonB Fwd 62 5-CTTTATACCTCGGTACATCAGGTT-3 Ins LAP Fwd This study 5-TGGATGATAGCGGATAAAACAG-3 
tonB Rev 62 5-ATTCGCCGGCTGRGCRGAGAG-3 Ins LAP Rev This study 5- GCCAATGCAAGAGCGATAG-3 
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4. Results 
 
4.1 Results of strain collection and MIC distribution 
 
Altogether 756 Enterobacteriaceae clinical isolates were collected from the microbiological 
diagnostic departments: 75 from Bolzano, 31 from Rovereto, 94 from Trento, 101 from Vicenza 
and 455 from Verona. The largest part were E. coli, but many Enterobacteriaceae species such as 
Klebsiella spp., Proteus spp., Citrobacter spp. were also in the collection  (Table 3, Graph 1). 
 
  
 
 
Graph 1. Distribution of the 756 Enterobacteriaceae isolates 
E. coli
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Enterobacter spp.
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Table 3. Number of strains collected in each center by species 
 
 Bolzano Rovereto Trento Vicenza Verona Total 
Escherichia coli  51 23 72 80 271 497 
Klebsiella spp. 12 1 3 6 46 68 
Citrobacter spp. 1 1 3 1 12 18 
Proteus spp. 6 4 9 5 45 69 
Morganella spp. 1 2 2 2 17 24 
Providentia spp. 3 0 1 6 11 21 
Enterobacter spp. 1 0 3 1 47 52 
Serratia marcescens 0 0 1 0 6 7 
Total  75 31 94 101 455 756 
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MICs of ciprofloxacin and levofloxacin were measured for all strains. We could demonstrate a 
range of 0.06-128 mg/L. Graph 2 shows the distribution of the MIC values in the collection. In 
total sixty-five percent of the strains in the collection had 64 or 128 mg/L MICs for ciprofloxacin 
while for levofloxacin 65.3% had 16, 32 or 64 mg/L. Low-level resistant strains (0.06 - 0.5 mg/L) 
were found to represent 10.5% of the collection. 
 
 
 
 
 
Graph 2. MIC distribution of ciprofloxacin and levofloxacin of 756 Enterobacteriaceae strains 
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4.2 Results of screening for qnr, aac(6’)-Ib-cr variant, qepA and oqxAB genes 
 
Screening by PCR for PMQR genes found 104 isolates positive for any of the tested PMQR 
genes, showing their 13.3% prevalence in the collection. 108 PMQR genes were found since four 
E. coli strains carried a qnrS1 and an aac(6’)-Ib-cr too. 38 out of the 756 strains were positive for 
any of the tested qnr determinants, showing a 5.02% prevalence. 7 qnrB, 26 qnrS and 5 qnrD 
were found and further investigated by DNA sequencing and analysis verified: 2 qnrB2, 2 qnrB6, 
2 qnrB8, 1 qnrB19, 26 qnrS1 and 5 qnrD. Screening by PCR for aac(6’)-Ib-cr genes proved 70 
positives and verified by DNA sequencing showing 9.2% prevalence. Among the positives 60 
were E. coli, 8 Klebsiella spp., 1 P. mirabilis and 1 M. morganii. Neither qnrA, qnrC or qepA, 
oqxAB were found in the collection (Table 4). 
 
The overview of the positive strains shows the highest prevalence in Klebsiella spp. and 
Citrobacter spp. with 33.8% and 27.7%, respectively. Klebsiella spp. had 15 qnrS1 and 8 
aac(6’)-Ib-cr. Noteworthy, E. coli accounted for 65.7% (497/756) of the collection, only 14.1% 
carried a PMQR gene, 10 qnrS1 and 60 aac(6’)-Ib-cr genes were detected. Interestingly, Proteus 
spp. carried three different types of PMQR genes (1 qnrS1, 4 qnrD and 1 aac(6’)-Ib-cr), though 
these 3 determinants were detected only in 8.7% of this genus. Among Morganella morganii 1 
qnrD and 1 aac(6’)-Ib-cr positive strains were identified. 
 
 
 
Table 4.  Isolates found positive for PMQR genes in the collection 
 
 
qnrA qnrB qnrS qnrC qnrD aac(6’)-Ib-cr qnrS1+ 
aac(6’)-Ib-cr 
qepA oqxAB Prevalence 
Escherichia coli 0 0 6 0 0 56 4 0 0 66/497 = 13.3%                                   
Klebsiella spp. 0 0 15 0 0 8 0 0 0 23/68 = 33.8% 
Citrobacter spp. 0 5 0 0 0 0 0 0 0 5/18 = 27.7 % 
Proteus spp. 0 0 1 0 4 1 0 0 0 6/69 =8.7 % 
Morganella spp. 0 0 0 0 1 1 0 0 0 2/24 = 8.3 % 
Enterobacter spp 0 2 0 0 0 0 0 0 0 2/52  = 3.8 % 
Providentia spp. 0 0 0 0 0 0 0 0 0 0/21 = 0% 
S. marcescens 0 0 0 0 0 0 0 0 0 0/7 = 0% 
Total 0 7 22 0 5 66 4 0 0 104/756 = 13.7%  
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MIC values of qnr and aac(6´)-Ib-cr positive strains are listed in Table 5, 6 and 7. Graph 3 
shows the distribution of the positive strains ranging over 11 different ciprofloxacin MIC values 
from susceptible to resistant. In the case of aac(6’)-Ib-cr positives, they were found only in the 
resistance range (64 and 128 mg/L). Three qnrB positive Citrobacter spp. and two qnrS positive 
Klebsiella pneumoniae were found at low-level resistance range (0.06 - 0.5 mg/L). These five 
isolates account for 13.1% (5/38). 
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Graph 3. Comparison of ciprofloxacin MIC values of qnr positive and aac(6’)-Ib-cr positive 
strains  
 
 
 
 
Table 5. MIC (µg/ml) values of aac(6’)-Ib-cr variant postive K.pneumoniae, P.mirabilis and M. 
morganii 
 
Strain PMQR cip lev ceftazidime cefotaxim cefepime aztreonam imipenem 
K.pneumoniae VR C191  aac(6’)-Ib-cr >128 32 128 64 16 128 <0.0625 
K.pneumoniae VR E102  aac(6’)-Ib-cr 128 8 >128 >128 >128 >128 <0.0625 
K.pneumoniae VR E154  aac(6’)-Ib-cr 128 8 >128 >128 >128 >128 0.125 
K.pneumoniae VR E157  aac(6’)-Ib-cr >128 16 >128 >128 >128 >128 <0.0625 
K.pneumoniae VR E165  aac(6’)-Ib-cr >128 16 >128 >128 64 >128 1 
K.pneumoniae VR E176  aac(6’)-Ib-cr >128 32 128 >128 >128 >128 <0.0625 
K.pneumoniae V29 aac(6’)-Ib-cr 128 16 >128 >128 >128 >128 0.5 
K.pneumoniae V91 aac(6’)-Ib-cr 128 16 >128 >128 >128 >128 0.5 
         
P.mirabilis T40  aac(6’)-Ib-cr 128 16 >128 >128 >128 >128 0.0625 
 
        
M. morganii T53 aac(6’)-Ib-cr 64 8 16 128 32 64 1 
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Table 6. MIC (µg/ml) values of aac(6’)-Ib-cr variant postive E. coli strains 
 
Strain PMQR cip lev ceftazidime cefotaxim cefepime aztreonam imipenem 
E. coli T6 aac(6’)-Ib-cr 128 16 128 >128 32 >128 0.125 
E. coli T10 aac(6’)-Ib-cr >128 128 >128 >128 >128 >128 0.0625 
E. coli T27 aac(6’)-Ib-cr >128 32 128 >128 >128 >128 0.0625 
E. coli T30 aac(6’)-Ib-cr >128 128 1 1 1 1 0.25 
E. coli T39 aac(6’)-Ib-cr >128 64 >128 >128 >128 >128 0.125 
E. coli T47  aac(6’)-Ib-cr 128 32 >128 >128 >128 >128 0.125 
E. coli T87 aac(6’)-Ib-cr 64 16 >128 >128 >128 >128 0.0625 
E. coli V18 aac(6’)-Ib-cr >128 16 64 >128 32 >128 0.125 
E. coli V21 aac(6’)-Ib-cr >128 16 32 >128 16 128 0.0625 
E. coli V25 aac(6’)-Ib-cr 128 16 1 1 1 2 <0.0625 
E. coli V27 aac(6’)-Ib-cr 64 32 >128 >128 >128 >128 <0.0625 
E. coli V32 aac(6’)-Ib-cr 128 16 1 1 2 0.5 0.0625 
E. coli V41 aac(6’)-Ib-cr 64 16 0.5 0.125 0.25 1 0.125 
E. coli V47 aac(6’)-Ib-cr >128 128 32 >128 1 128 <0.0625 
E. coli V55 aac(6’)-Ib-cr 128 16 16 >128 8 64 <0.0625 
E. coli V65 aac(6’)-Ib-cr 128 64 1 2 2 0.5 0.25 
E. coli V85 aac(6’)-Ib-cr 128 64 1 0.25 0.5 1 0.0625 
E. coli B33 aac(6’)-Ib-cr 128 64 2 0.125 0.25 0.25 0.0625 
E. coli B38 aac(6’)-Ib-cr >128 32 >128 >128 128 >128 0.0625 
E. coli B44 aac(6’)-Ib-cr >128 16 128 >128 64 >128 <0.0625 
E. coli B65 qnrS1, aac(6’)-Ib-cr >128 128 >128 >128 128 >128 0.0625 
E. coli R25 aac(6’)-Ib-cr >128 64 128 >128 128 >128 0.0625 
E. coli VR B18 aac(6’)-Ib-cr 64 16 >128 >128 >128 >128 <0.0625 
E. coli VR B88 aac(6’)-Ib-cr 64 16 64 >128 64 >128 <0.0625 
E. coli VR B127 aac(6’)-Ib-cr 64 8 >128 >128 >128 >128 <0.0625 
E. coli VR B227 aac(6’)-Ib-cr 128 16 >128 128 >128 >128 <0.0625 
E. coli VR B232 aac(6’)-Ib-cr 64 8 >128 >128 128 >128 <0.0625 
E. coli VR B248 aac(6’)-Ib-cr >128 16 0.25 0.5 4 <0.0625 <0.0625 
E. coli VR B262 aac(6’)-Ib-cr >128 16 0.125 2 16 0.5 <0.0625 
E. coli VR B269 aac(6’)-Ib-cr 128 8 128 >128 128 >128 <0.0625 
E. coli VR B292 aac(6’)-Ib-cr 64 8 0.125 <0.0625 <0.0625 <0.0625 <0.0625 
E. coli VR B649 aac(6’)-Ib-cr 64 8 0.5 0.25 0.5 0.125 <0.0625 
E. coli VR B656 aac(6’)-Ib-cr 64 8 64 >128 64 >128 <0.0625 
E. coli VR B715 aac(6’)-Ib-cr 64 2 64 >128 128 >128 <0.0625 
E. coli VR B 717 aac(6’)-Ib-cr 128 16 128 >128 >128 >128 <0.0625 
E. coli VR B754 aac(6’)-Ib-cr 128 16 0.5 0.25 1 0.5 <0.0625 
E. coli VR B770 qnrS1, aac(6’)-Ib-cr 64 16 128 >128 64 >128 <0.0625 
E. coli VR B775 qnrS1, aac(6’)-Ib-cr 64 16 128 >128 64 >128 <0.0625 
E. coli VR B780 aac(6’)-Ib-cr 128 16 >128 >128 >128 >128 <0.0625 
E. coli VR B784 aac(6’)-Ib-cr >128 16 128 128 128 128 <0.0625 
E. coli VR B786 aac(6’)-Ib-cr 128 32 0.125 0.125 <0.0625 <0.0625 <0.0625 
E. coli VR B787 aac(6’)-Ib-cr 64 8 128 128 128 >128 <0.0625 
E. coli VR B793 aac(6’)-Ib-cr >128 16 8 16 8 32 <0.0625 
E. coli VR B808 aac(6’)-Ib-cr >128 8 64 128 64 128 <0.0625 
E. coli VR B814 qnrS1, aac(6’)-Ib-cr 128 16 >128 >128 128 >128 <0.0625 
E. coli VR C17 aac(6’)-Ib-cr 64 8 0.25 0.125 0.5 0.25 <0.0625 
E. coli VR C18 aac(6’)-Ib-cr 128 8 >128 >128 >128 >128 <0.0625 
E. coli VR C19 aac(6’)-Ib-cr 128 8 >128 >128 128 >128 <0.0625 
E. coli VR C24 aac(6’)-Ib-cr 64 4 >128 >128 128 >128 <0.0625 
E. coli VR C66 aac(6’)-Ib-cr 64 4 64 >128 128 >128 <0.0625 
E. coli VR C93 aac(6’)-Ib-cr 64 4 0.5 <0.0625 0.5 0.25 <0.0625 
E. coli VR C105 aac(6’)-Ib-cr 64 4 64 >128 128 >128 <0.0625 
E. coli VR C109 aac(6’)-Ib-cr 64 16 64 128 64 >128 <0.0625 
E. coli VR E13 aac(6’)-Ib-cr 64 8 64 128 128 64 <0.0625 
E. coli VR E25 aac(6’)-Ib-cr 64 8 64 128 128 >128 <0.0625 
E. coli VR E39 aac(6’)-Ib-cr 64 8 >128 >128 128 >128 <0.0625 
E. coli VR E47 aac(6’)-Ib-cr 64 8 8 1 2 >128 <0.0625 
E. coli VR E64 aac(6’)-Ib-cr 128 16 32 >128 >128 >128 <0.0625 
E. coli VR E98 aac(6’)-Ib-cr 64 8 64 >128 >128 >128 <0.0625 
E. coli VR E108 aac(6’)-Ib-cr 128 8 64 >128 >128 >128 <0.0625 
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Table 7. MIC (µg/ml) values of qnr positive isolates 
 
Strain PMQR cip lev ceftazidime cefotaxim cefepime aztreonam imipenem 
E. coli B24 qnrS1 >128 >128 128 16 2 0.125 <0.0625 
E. coli B61 qnrS1 64 16 0.5 0.125 <0.0625 <0.0625 <0.0625 
E. coli B65 qnrS1,aac(6’)-Ib-cr >128 128 >128 >128 128 >128 <0.0625 
E. coli V38 qnrS1 64 32 0.5 <0.06 <0.0625 <0.0625 <0.0625 
E. coli T57 qnrS1 128 64 1 0.25 <0.0625 0.125 <0.0625 
E. coli VR301 qnrS1 32 16 >128 >128 128 >128 <0.0625 
E. coli VR770 qnrS1,aac(6’)-Ib-cr 64 16 128 >128 64 >128 <0.0625 
E. coli VR775 qnrS1,aac(6’)-Ib-cr 64 16 128 >128 64 >128 <0.0625 
E. coli VR805 qnrS1 8 8 0.25 <0.0625 <0.0625 0.125 <0.0625 
E. coli VR814 qnrS1,aac(6’)-Ib-cr 128 16 >128 >128 128 >128 <0.0625 
K.pneumoniae B49 qnrS1 32 16 >128 64 16 >128 0.0625 
K.pneumoniae B56 qnrS1 0.25 0.25 >128 128 16 >128 0.0625 
K.oxytoca B67 qnrS1 1 1 >128 64 16 0.125 1 
K.oxytoca B68 qnrS1 64 16 >128 64 16 0.5 0.5 
K.pneumoniae B69 qnrS1 8 8 >128 64 8 >128 0.25 
K.pneumoniae T52 qnrS1 16 64 >128 128 2 128 <0.0625 
K.pneumoniae VR586 qnrS1 16 8 >128 >128 128 >128 <0.0625 
K.pneumoniae VR782 qnrS1 16 16 >128 >128 32 >128 <0.0625 
K.pneumoniae VR818 qnrS1 32 16 0.25 <0.0625 <0.0625 0.125 <0.0625 
K.pneumoniae VR824 qnrS1 >128 128 2 0.125 0.125 0.5 <0.0625 
K.pneumoniae VRC160 qnrS1 0.25 0.25 >128 128 16 >128 <0.0625 
K.pneumoniae VRE73 qnrS1 16 2 >128 64 8 >128 <0.0625 
K.pneumoniae VRE94 qnrS1 16 8 0.5 <0.0625 <0.0625 0.5 <0.0625 
K.pneumoniae VRE185 qnrS1 32 16  64 128 32 >128 <0.0625 
K.pneumoniae VRE196 qnrS1 16 8 128 >128 64 >128 <0.0625 
P. mirabilis T18 qnrS1 64 32 2 4 0.25 <0.0625 0.0625 
P. mirabilis VR67 qnrD 4 8 <0.0625 <0.0625 <0.0625 <0.0625 <0.0625 
P. mirabilis VR758 qnrD 1 2 <0.0625 <0.0625 <0.0625 <0.0625 <0.0625 
P. mirabilis VR1048 qnrD 4 4 <0.0625 <0.0625 <0.0625 <0.0625 <0.0625 
P. mirabilis T80 qnrD 2 2 <0.0625 <0.0625 <0.0625 <0.0625 <0.0625 
M. morganii VR831 qnrD 2 4 <0.0625 <0.0625 <0.0625 <0.0625 <0.0625 
C. freundii R11 qnrB6 128 64 2 0.5 <0.0625 1 <0.0625 
C. freundii T35 qnrB6 <0.0625 <0.0625 >128 128 2 128 <0.0625 
C. koserii V96 qnrB19 0.25 0.5 128 16 1 >128 <0.0625 
C. freundii VR669 qnrB8 32 0.0625 >128 64 1 128 <0.0625 
C. freundii VRE14 qnrB8 0.25 0.25 >128 32 0.25 32 <0.0625 
E. cloacae VRD25 qnrB2 16 2 >128 >128 64 >128 <0.0625 
E. cloacae VR739 qnrB2 256 64 >128 >128 32 >128 <0.0625 
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4.3 Characterization of qnr positive isolates 
 
All thirty-eight qnr positive strains were further screened for beta-lactamase genes such as: 
blaSHV, blaTEM, blaCTX-M, blaOXA, blaLAP, blaVIM and blaIMP and plasmid incompatibility groups 
(inc type) were also determined (Table 8, Graph 4). Ten qnrS1 positive E. coli isolates were 
found to be positive for a variety of beta-lactamase genes. The most prevalent was blaTEM-1 
(7/10), but others such as blaCTX-M-15 (4/10), blaOXA-1 (4/10), blaSHV-12 (1/10) and blaVIM-1 (1/10) 
were also identified. Their plasmid incompatiblity types were also recognized, whereas incN 
(7/10) and incF (9/10) replicons were predominant, and others like incFia (7/10), incFib (3/10) 
and incColE (2/10) were also detected. 
The four E. coli isolates carrying both qnrS1 and aac(6’)-Ib-cr variant were all found to be 
positive for blaCTX-M-15, blaOXA-1 and blaTEM-1, and even their plasmid incompatibility types 
showed similarity, since incN, incFia and incF were common, and only one had incColE.  
Fifteen Klebsiella spp. carring qnrS1 determinant were detected and found positive for blaVIM-1 
(5/15), blaSHV-12 (6/15), blaSHV-28 (1/15), blaTEM-3 (1/15), blaCTX-M-15 (2/15) and blaLAP-2 (3/15). In 
case of their incompatibility groups, incN (12/15) and incColE (13/15) were the dominant ones, 
while incR (3/15) and incL/M (2/15) were also identified. 
One qnrS1 positive P. mirabilis carried TEM-52 and harboured incN plasmid. Four qnrD 
positive P. mirabilis and one M. morganii were detected and all of them were found negative for 
the tested beta-lactamases and were untypeable for the incompatibility groups. 
Among qnrB positive isolates, five Citrobacter spp. and two Enterobacter cloacae were detected. 
Associations with beta-lactamases were rare, only one blaSHV-12 and one blaTEM-1 positive 
Citrobacter spp. were detected, while one E. cloacae was found blaSHV-12 and blaTEM-1 positive. 
Common incompatibility group, incHI2 was found for E. cloacae but all the Citrobacter isolates 
were untypeable. 
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Table 8. Qnr positive strains and their association with beta-lactamse genes and inc types 
 
 inc type PMQR VIM SHV TEM CTX-M OXA LAP 
E. coli  B24      N, Fia, Fib, F qnrS1 VIM-1 neg neg neg neg neg 
E. coli  B61 N, Fia, Fib qnrS1 neg neg neg neg  neg neg  
E. coli  V38 F, ColE qnrS1 neg neg TEM-1 neg neg neg  
E. coli  T57 Fib, F qnrS1 neg neg TEM-1 neg neg neg 
E. coli  B65 N, Fia, F, ColE qnrS1, aac(6’)-Ib-cr neg neg TEM-1 CTX-M-15 OXA-1 neg 
E. coli VR 770 N, Fia, F qnrS1, aac(6’)-Ib-cr neg neg TEM-1 CTX-M-15 OXA-1 neg 
E. coli VR 775 N, Fia, F qnrS1, aac(6’)-Ib-cr neg neg TEM-1 CTX-M-15 OXA-1 neg  
E. coli VR 814 N, Fia, F qnrS1, aac(6’)-Ib-cr neg neg TEM-1 CTX-M-15 OXA-1 neg 
E. coli VR 805  F qnrS1 neg neg TEM-1 neg neg neg 
E. coli VR 301 N, Fia, F qnrS1 neg SHV-12 neg neg neg neg  
K. pneumoniae B49 N, ColE qnrS1 VIM-1 SHV-12 neg neg neg neg 
K. pneumoniae B56 N, ColE qnrS1 VIM-1 SHV-12 neg neg neg neg  
K. pneumoniae B69 N, ColE qnrS1 VIM-1 SHV-12 neg neg neg neg 
K. pneumoniae T52 N, ColE qnrS1 neg SHV-28 TEM-3 neg neg neg  
K. oxytoca B67 N qnrS1 VIM-1 neg neg neg neg neg 
K. oxytoca B68 N qnrS1 VIM-1 neg neg neg neg neg  
K.pneumoniae VR 586 ColE qnrS1 neg SHV-12 neg neg neg LAP-2 
K.pneumoniaeVRE185 ColE qnrS1 neg neg neg CTX-M-15 neg LAP-2 
K.pneumoniaeVRE196 ColE qnrS1 neg neg neg CTX-M-15 neg LAP-2 
K.pneumoniae VR782  N, R, ColE qnrS1 neg SHV-12 neg neg neg neg 
K.pneumoniae VR818 N, R, ColE qnrS1 neg neg neg neg neg neg  
K.pneumoniae VR824  N, R, ColE qnrS1 neg neg neg neg neg neg 
K.pneumoniaeVRC160 N, L/M, ColE qnrS1 neg neg neg neg neg neg  
K.pneumoniaeVRE73 N, L/M, ColE qnrS1 neg SHV-12 neg neg neg neg 
K.pneumoniaeVRE94 N,ColE qnrS1 neg neg neg neg neg neg  
P. mirabilis  T18 N qnrS1 neg neg TEM-52 neg neg neg 
P. mirabilis  T80 Untypeable qnrD neg neg neg neg neg neg  
P. mirabilis VR 67 Untypeable qnrD neg neg neg neg neg neg 
P. mirabilis VR 758 Untypeable qnrD neg neg neg neg neg neg  
P. mirabilis VR1048 Untypeable qnrD neg neg neg neg neg neg 
M.morganii VR 831 Untypeable qnrD neg neg neg neg neg neg  
C. freundii R11 Untypeable qnr B6 neg neg TEM-1 neg neg neg 
C. freundii T35 Untypeable qnr B6 neg neg neg neg neg neg  
C. koserii V96 Untypeable qnr B19 neg SHV-12 neg neg neg neg 
C.freundii VR 669 Untypeable qnrB8 neg neg neg neg neg neg  
C.freundiiVR E14 Untypeable qnrB8 neg neg neg neg neg neg 
E. cloacae VR 739 HI2, ColE qnrB2 neg neg neg neg neg neg 
E. cloacae VR D25 HI2 qnrB2 neg SHV-12 TEM-1 neg neg neg  
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Graph 4. Association of PMQR-positive isolates with beta-lactamase genes  
 
 
Graph 4 shows that qnrS1 positive strains were found to be positive for several beta-lactamase 
genes, namely, 27% VIM, 36% SHV, 23% TEM, 9% CTX-M and 13% LAP
.
 All the strains co-
harbouring qnrS1 with aac(6’)-Ib-cr were carrying genes of TEM, CTX-M
 
and OXA. The 
aac(6’)-Ib-cr positive strains had a high correlation with OXA beta-lactamase genes (96%) and 
with CTX-M beta-lactamase genes (69%). The qnrB positive isolates were 28.6% SHV and 
CTX-M postive. All the qnrD strains were negative for the tested beta-lactamase genes. 
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Transformation of DH5 alpha E. coli cells with recombinant vectors containing qnr genes 
The qnr genes found in our survey were analyzed in isogenic E. coli DH5 alpha cells after 
transformation with recombinant vectors ligated with qnrB, qnrS and qnD genes. After 
transformation, MIC increments for nalidixic acid, ciprofloxacin and levofloxacin were measuerd 
by broth microdilution method. 
The transformed DH5 alpha cells showed 1-5 fold MIC increment to nalidixic acid (from 32 
µg/ml to 64, 128 and 1024). In case of ciprofloxacin and levofloxacin no increment was 
measured (Table 9). 
 
 
 
Table 9. MIC values of DH5 alpha E. coli and its transformant (Tn) harbouring different qnr 
genes. 
 
Antimicrobial MIC (µg/ml) 
 
DH5 apha E. coli 
Recipient cell 
Tn DH5 alpha E. coli 
R11-QNR B6 
Tn DH5 alpha E. coli 
T35-QNR B6 
Tn DH5 alpha E. coli 
V38-QNR S1 
Tn DH5 alpha E. coli  
T80-QNR D 
nalidixic acid 32 128 1024  64 1024 
ciprofloxacin 0.016 0.016 0.016 0.016 0.016 
levofloxacin 0.032 0.032 0.032 0.032 0.032 
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Transformation of DH5 alpha E. coli cells with recombinant vectors containing aac(6’)-Ib-
cr variant gene 
The aac(6’)-Ib-cr variant genes found in our survey, were analyzed in isogenic E. coli DH5 alpha 
cells after transformation with recombinant vectors ligated with aac(6’)-Ib-cr genes. After 
transformation, MIC increments for kanamycin, gentamicin, amikacin, ciprofloxacin and 
levofloxacin were measured by broth microdilution method.   
The transformed DH5 alpha cells showed 2-3 fold MIC increment to gentamicin (from 0.125 
µg/ml to 0.5, 1 and 2), 7-9 fold to kanamycin (from 0.5 µg/ml to 64 and 256), 1-3 fold to 
amikacin (from 0.125 µg/ml to 0.25, 0.5 and 1). In case of ciprofloxacin and levofloxacin no 
increment was measured (Table 10). 
 
 
 
Table 10. MIC values of DH5 alpha E. coli and its transformant (Tn) counterparts harbouring 
aac(6’)-Ib-cr genes. 
 
Antimicrobial MIC (µg/ml) 
 
DH5 alpha E. coli 
 
Tn DH5 alpha E. coli  
V25-aac(6’)-Ib-cr 
Tn DH5 alpha E.coli 
 V27-aac(6’)-Ib-cr 
Tn DH5 alpha E. coli  
V41-aac(6’)-Ib-cr 
Tn DH5 alpha E. coli  
T87-aac(6’)-Ib-cr 
gentamicin 0.125 1 0.5 0.125 2 
kanamycin 0.5 256 256 256 64 
amikacin 0.125 0.5 0.25 0.125 1 
ciprofloxacin 0.016 0.016 0.016 0.016 0.016 
levofloxacin 0.032 0.032 0.032 0.032 0.032 
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4.4 Characterization of qnrD positive isolates 
 
Four P. mirabilis (labelled: VR67, VR758, VR1048, T80) and one M. morganii (labelled: 
VR831) isolates were found to be positive by PCR for the qnrD determinant. Sequencing 
confirmed all to belong to the same allel. PCR-based replicon typing found all isolates 
untypeable and conjugation experiment did not find transconjugable plasmids. The strains were 
susceptibile to third and fourth generation cefalosporins, aztreonam and carbapenem but resistant 
to fluoroquinolones. 
 
Plasmid characterization 
Linearization of plasmids by digestion with Nhe I and Xba I restriction enzymes 
Plasmid extractions of all qnrD positive isolates were treated with restriction enzymes having 
recognition site in the qnrD gene. Figure 13 shows the agarose gelelectrophoresis of qnrD-
harbouring plasmids after digestion with Nhe I and Xba I, approximately 2800 bp plasmid is 
common to all the isolates. 
 
                               Nhe I digestion (a)                        Xba I digestion (b) 
  
 
                 
 
 
Figure 13. Plasmid profile of qnrD positive isolates digested with Nhe I (a) and Xba I (b) 
restriction enzymes: 1: VR67, 2: VR758, 3: VR831, 4: VR1048, 5: T80, M: 1kb ladder 
(Invitrogen) 
 
      1a,     2a ,    3a,     4a,     5a       M     1b,     2b,    3b,      4b,      5b   
2800 bp 
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Southern blot of qnrD-harbouring plasmids 
Plasmid extractions of qnrD positive isolates were treated with ATP-dependent DNase, to 
eliminate chromosomal DNA. Plasmid extractions before and after treatment were loaded onto 
0.6% (w/v) agarose gel which showed approximately 2800 bp common plasmid. After 
denaturation of plasmid DNA and overnight blot on positively-charged nylon membrane, 
hybridization was carried out at 44.6oC with digoxigenin-labeled qnrD probe. After developing 
chemiluminescens detection film positive bands verified qnrD gene to be localized on the 
common plasmid, since both plasmid extractions without (a) and with (b) chromosomal treatment 
had given positive signal (Figure 14). 
 
 
 
           
          M    1 2a  2b   3a 3b   4a  4b  5a 5b    6a 6b            1   2a   2b 3a  3b 4a  4b  5a  5b 6a  6b                       
 
Figure 14. Plasmid profiles (left) and corresponding Southern blot (right) of 5 qnrD positive 
strains. Each strain was running as untreated (a) and treated (b) to remove any trace of 
chromosome DNA. M: 1kb (Sigma); 1:  qnrD gene; 2a-b: strain VR67; 3a-b: strain VR758; 4a-b: 
strain VR831; 5a-b: strain VR1048; 6a-b: strain T80 
 
 
 
 
 
 
 
 
500 bp 
2500 bp 
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Results of inverse PCR on qnrD-harbouring plasmids  
Inverse PCR was performed by complementar and antiparallel oligonucleotids of qnrD Fwd and 
qnrD Rev primers labeled INVDF/Rev and INVDR/Fwd (Table 2, Figure 16), to amplify the 
plasmid DNA located upstream and downstream to the qnrD gene. Thermal profile was used as 
follows: 94oC for 1 min, 53.1oC for 1 min and elongation at 72oC for 3 min for 30 cycles, resulted 
in 2200 bp products (Figure 15). Sequencing was carried out and two additional set of primers 
were designed Pl 1 Rev with Pl 2 Fwd and Pl 3 Fwd with Pl 4 Rev (Table 2, Figure 16) to obtain 
overlapping regions of the qnrD-plasmid. PCR was performed with these set of primers, with 
thermal profile as follows: 30 cycles of 94oC for 1 min, 53.1oC for 1 min and 72oC for 3 min and 
after sequencing the positive PCR products overlapping regions were obtained. The whole 
sequences of qnrD-plasmid were 2687 bp for the four P. mirabilis while 2684 bp for the M. 
morganii. 
 
 
 
                                     
 
 
 
Figure 15. Inverse PCR on qnrD-harbouring plasmids 1: VR67, 2: VR758, 3: VR831, M: 1kb 
(Sigma), 4: VR1048, 5: VRT80 
 
 
 
 
 
2200bp 
      1,    2,    3       M   4,   5 
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Figure 16. Primers highlighted on the schematic figure of pT80. 
 
 
Sequence analysis  
The qnrD-harbouring plasmid sequence analysis found 100% similarity with the 1450 bp (54%) 
of the first described qnrD plasmid. Besides the qnrD gene the upstream region included a 
promoter sequence and the downstream region included an Orf2 gene, without known function. 
The remaining 1237 bp sequence of the plasmid was unknown. 
 
 
Deposition of plasmid DNA sequence in Genbank was done, with accession number JN183060 
and JN183061 for P. mirabilis and M. morganii, respectively. 
  
      
 
 
pT80 = 2687 bp 
INVDF/Rev - qnrD Fwd 
qnrD Rev - 
INVDR/Fwd 
Pl 3 primer 
Fwd 
Pl 4 primer 
Rev 
Pl 1 
primer 
Rev 
Pl 2 primer 
Fwd 
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Table 11 shows all the qnrD positve strains were resistant to the tested fluoroquinolones  
(cip : ciprofloxacin, lev : levofloxacin) and susceptible to the tested beta-lactam antibiotics. 
 
 
 
Table 12. QRDR aminoacid substitutions in qnrD positive strains 
 
(n.d.: not detected) 
 
 
Table 12 shows the QRDR regions of the qnrD postive strains. The detected aminoacid changes 
can explain the fluoroquinolone resistant phenotype. In case of M. morganii we could not obtain 
PCR product for gyrA and parC. 
 
 
 
Table 11. MIC of the qnrD postive strains for fluoroquinolones and beta-lactam antibiotics 
 
Strains MIC (µg/ml)   
 cip lev ceftazidime cefotaxime cefepime aztreonam imipenem 
P.mirabilis VR67 4 8 <0.0625 <0.0625 <0.0625 <0.0625 <0.0625 
P.mirabilis VR758 1 2 <0.0625 <0.0625 <0.0625 <0.0625 <0.0625 
P.mirabilis VR1048 4 4 <0.0625 <0.0625 <0.0625 <0.0625 <0.0625 
P. mirabilis T80 2 2 <0.0625 <0.0625 <0.0625 <0.0625 <0.0625 
M. morganii VR831 2 4 <0.0625 <0.0625 <0.0625 <0.0625 <0.0625 
Strains QRDR 
 gyrA gyrB parC 
P. mirabilis ATCC 29906 83 
S 
87 
E 
464 
S 
466 
E 
78 
G 
80 
S 
P. mirabilis VR67 S 83 I E S E G  S 80 I 
P. mirabilis VR758 S 83 I E S E G S 80 R 
P. mirabilis VR1048 S 83 I E S E G S 80 I 
P. mirabilis T80 S 83 I E S E G S 80 I 
M. morganii VR831 n.d. n.d. S E n.d. n.d. 
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Clonality analysis 
Random Amplified Polymorphic DNA (RAPD) was performed with OPX13 primer. Figure 17 
shows that each strain has a different RAPD pattern, thus explaining the clonal unrelatedness 
 
 
 
                                                       M       1        2       3       4 
                                                  
 
Figure 17. RAPD profile of four qnrD positive P. mirabilis with primer Opx13.  
Legend : M: 1kb (Sigma); 1:strain T80; 2: strain VR67; 3: strain VR758; 4: strain VR1048. 
 
 
 
 
 
 
 
 
 
 
 
 
 
500 bp 
1000 bp 
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4.5 Characterization of qnrS1 postive isolates 
 
Our survey found twenty-six qnrS1 positive isolates namely, 10 E.coli, 15 Klebsiella spp. and 1 
P. mirabilis. Four E. coli strains besides qnrS1 were positive for the aac(6)-Ib-cr variant too. 
High correlation with beta-lactamases was detected. The 22 qnrS1 positive strains were found to 
be positive for several beta-lactamase genes too, namely 27% blaVIM, 36% blaSHV, 23% blaTEM, 
9% blaCTX-M. All the four qnrS1 and aac(6)-Ib-cr variant positive strains were blaCTX-M-15, blaOXA-1 
and blaTEM-1 positive (Table 8). 
 
Characterization of qnrS1 postive plasmids 
Characterization of qnrS1 positive strains was performed by PCR-based replicon typing where 
incN plasmid type was the predominant, but incColE, incFia, incFib, incF, incL/M, and incR 
were also identified (Table 8). Figure 18 shows the qnrS1-harbouring plasmids, identified as 
incN type. Conjugation experiment found incN, approximately 100 kb plasmids harbouring 
qnrS1 and blaVIM-1 genes to be transferable from two Klebsiella oxytoxa and one Klebsiella 
pneumoniae strains to E. coli J53 AzidR.  The increase of MIC values in transconjugants were 
checked by microdilution method and showed these plasmids to be able to raise the MIC in host 
cells up to the low-level resistance (0.06-0.5µg/ml). The MIC increased by 1-2 fold in the case of 
nalidixic acid,  2-4 fold  in the case of ciprofloxacin, and 2-3 fold in the case of levofloxacin 
(Table 13). 
 
 
Table 13. MIC increment in the transconjugants carrying qnrS1-harbouring plasmid comparing 
to the recipient J53 E. coli 
 
 
Antimicrobial MIC (µg/ml) 
 J53 J53-pB49 J53-pB67 J53-pB68 
nalidixic acid 4 8 16 16 
ciprofloxacin 0.03 0.125 0.5 0.25 
levofloxacin 0.06 0.25 0.5 0.5 
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Figure 18. Southern blot analysis of qnrS1 positive E. coli strains:  
A) Plasmid profile (left) and Southern blot (right) with qnrS1 probe 
B) Plasmid profile (left) and Southern blot (right) with incN probe 
 
Figure 18.  
(A) 
 
                     
 
(B) 
 
 
                       
 
M: 1kb (Sigma); 1 (A) qnrS1 PCR product; 1 (B) incN PCR product; 2: pB65; 3; pVR770; 4: 
pVR775; 5: pVR814; 6: pB24; 7: pB61; 8: pVR301 
 
 
M     1    2      3     4    5      6     7    8 
M     1    2      3     4    5      6     7    8 
1    2      3     4    5      6     7    8 
 1     2      3      4     5       6       7      8 
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Results of pulsed-field gelelectrophoresis (PFGE) 
PFGE figure of qnrS1 positive E. coli strains after digestion of 30 units XbaI overnight at 37 oC, 
run at 14 oC for 21hours, 6V/cm, initial switch time 2sec, final switch time 30sec.  
Seven pulso-types (A-B-C-D-E-F-G) can be distinguished among the ten qnrS1 positive E. coli 
isolates and the R25 E. coli used as an indifferent strain (Figure 19). 
 
 
Figure 19. PFGE of the qnrS1 positive E. coli: 
1: VR805; 2: VR301, 3: VR770, 4: VR775, 5: VR814, 6: R25, 7: B24, 8: B61, 9: B65, 10: T57, 
11: V38  
 
 
                           
 
 
 
 
 
.  
1:A  2:B  3:B  4:B   5:B  6:B  7: C   8:D   9:E  10:F  11:G 
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4.6 Characterization of qnrS1 and blaLAP-2 positive K. pneumoniae strains 
 
Among twenty-six qnrS1 positive isolates, three K. pneumoniae strains were found positive by 
PCR for blaLAP using the LAP Fwd and LAP Rev set of primer. Sequencing verified them as 
LAP-2.  
 
The genetic context incorporating blaLAP-2 and qnrS1 genes was mapped by PCR using LAP Fwd 
and qnrS Rev primers, resulting in 2600 bp product. After sequencing of this PCR product 
additional primers namely, Ins lap Fwd and Ins lap Rev were designed by tools of Eurofins 
MWG Operon Germany (Table 2). This new set of primer was used in amplification of the 
internal part of the complex genetic material in a PCR reaction as follows: 40 cycles of 1 min at 
93°C, 1 min at 55°C, and 3 min at 72°C and finally, 72oC for 7 min. We obtained 800 bp PCR 
products, and after sequencing we found overlapping regions with the sequence of the 2600 bp 
PCR product. The sequence of the 800 bp PCR product was identified as ISEcl2, which separates 
blaLAP-2 and qnrS1 determinants. ISEcl2 is built up by orfA and orfB (Figure 20). 
 
 
                                                                      2600bp 
 
 
                                     blaLAP-2                           orfB             orfA                       qnrS1 
      800 bp 
ISEcl2 
 
 
Figure 20.  Genetic scheme of blaLAP-2  and qnrS1 genes. 
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The localization of this complex genetic material was further investigated by Southern blot. 
Plasmid extractions of each strain before and after treatment of ATP-dependent DNase were run 
in a 0.6% (w/v) agarose gel, denatureated and blotted on a positively charged nylone membrane. 
Hybridization at 47oC with digoxigenin-labeled LAP-probe was done. A chemiluminescens 
detection film was developed in dark chamber, where positive bands verified the localization on 
approximately 100 kb plasmid (Figure 21). 
 
 
 
 
                                  
 
Figure 21. Plasmid extraction (left) and Southern-blot (right) of blaLAP-2 and qnrS1 positive 
strains. Legend: M: 1kb (Sigma), 1: blaLAP PCR product, 2: pVR185 without DNase treatment, 3: 
pVR185 after DNase treatment, 4: pVR196 without DNase treatment, 5: pVR196 after DNase 
treatment, 6: pVR586 without DNase treatment 7: pVR586 after DNase treatment. 
 
 
Transferability of qnrS1 and blaLAP-2 positive plasmids was also checked by conjugation. No 
transconjugants were selected on Luria-Bertani agar plates containing 100 µg/ml sodium-Azid 
and 16 µg/ml nalidixic acid by using J53 AzidR E. coli as recipient cells.  
PCR–based replicon typing was also performed and all three Klebsiella pneumoniae strains were 
found positive only for incColE. Southern blot was carried out with digoxigenin labeled colE-
probes and clarified the 3 kb plasmid to belong to this type.  
 
 
M,  1,   2,   3,   4,  5,   6,  7 1,    2,     3,     4,     5,     6,   7 
500 bp 
1000 bp 
3000 bp 
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Clonality analysis of the three Klebsiella pneumoniae strains was performed by pulsed-field 
gelelectrophoresis, 30 U Xba I digestion overnight and run in CHEF DRTM Electrophoresis 
(BioRad) 6V/cm, 120o angel, initial switch time 2s and final switch time 35s for 21h run. An 
identical pulso-type was detected for all the three Klebsiella pneumoniae isolates. 
Strain genotyping was performed by Multilocus Sequence typing (MLST) to determine the 
sequence type (ST) of the isolates. Allelic numbers were obtained on the basis of sequences of 7 
housekeeping genes at the http://www.pasteur.fr/recherche/genopole/PF8/mlst/Kpneumoniae . 
MLST identified the strains as a ST 147. 
 
 
Tabel 14 shows MIC values of the three qnrS1 and LAP-2 positive K.pneumoniae strains. All of 
them were resistant to fluoroquinolones and to third- and fourth-generation cephalosporins, but 
susceptible to imipenem. 
 
 
 
 
Tabel 15 shows the incompatibility types and the tested beta-lactamase genes of the three qnrS1 
and LAP-2 positive K. pneumoniae strains. All of them were carrying incColE type plasmid, two 
were found positive for CTX-M-15 and one was SHV-12 positive.  
 
 
 
Table 14.  MIC (µg/ml) of K. pneumoniae strains harbouring blaLAP2 and qnrS1 genes 
 
Strain PMQR ciprofloxacin levofloxacin ceftazidime cefotaxime cefepime aztreonam imipenem 
K.pneumoniae VRE185 qnrS1 32 16  64 128 32 >128 <0.0625 
K.pneumoniae VRE196 qnrS1 16 8 128 >128 64 >128 <0.0625 
K.pneumoniae VR 586 qnrS1 16 8 >128 >128 128 >128 <0.0625 
Table 15. Genetic determinants of K. pneumoniae strains harbouring blaLAP2 and qnrS1 genes 
 
Strain  inc type PMQR VIM SHV TEM CTX-M OXA LAP 
K.pneumoniae VRE185 ColE qnrS1 neg neg neg CTX-M-15 neg LAP-2 
K.pneumoniae VRE196 ColE qnrS1 neg neg neg CTX-M-15 neg LAP-2 
K.pneumoniae VR 586 ColE qnrS1 neg SHV-12 neg neg neg LAP-2 
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4.7 Characterization of aac(6’)-Ib-cr variant positive isolates 
 
Altogether 70 from the 756 isolates tested were found positive for this plasmid-mediated 
quinolone resistance determinant showing 9.25% prevalence. Among them were 60 E. coli, 8 
Klebsiella spp, one P. mirabilis and M. morganii. 
All the positive strains were found resistant to fluoroquinolones and 78% (55/70) were resistant 
to third generation cefalosporins too (Table 5, Table 6). High correlation of CTX-M-15 and 
OXA-1 beta-lactamase was remarkable in the case of E. coli, (42/60), all the Klebsiella spp., 
(8/8) and M. morganii. Exception was P.mirabilis where TEM-52 and OXA-1 was detected. 
PCR-based replicon (inc) typing found incFia, incFib, incF and incColE for E. coli, while for 
Klebsiella spp. incColE was the predominant. In the case of P. mirabilis incFia and incF types 
were detected, but M. morganii was untypeable (Table 16, Table 17). 
 
Four E. coli strains were positive for qnrS1 determinant too, and shared an identical plasmid 
replicon profile incN, incFIA, incF. The two determinants [qnrS1 and aac(6’)-Ib-cr] have 
additive effect on developing fluoroquinolone resistance in Enterobacteriaceae, but this 
phenomenon was detected in 0.5% (4/756) of the isolates in our collection. 
 
 
Table 16.  The aac(6’)-Ib-cr variant positive K. pneumoniae, P. mirabilis, M. morganii with their 
beta-lactamase genes and incompatibility types 
 
 
Strain PMQR inc type SHV TEM CTX-M OXA 
K.pnenumoniae VR C191  aac(6’)-Ib-cr col E neg neg CTX-M-15 OXA-1 
K.pnenumoniae VR E102  aac(6’)-Ib-cr col E, F SHV-11 TEM-1 CTX-M-15 OXA-1 
K.pnenumoniae VR E154  aac(6’)-Ib-cr col E, F neg TEM-1 CTX-M-15 OXA-1 
K.pnenumoniae VR E157  aac(6’)-Ib-cr col E, F SHV-11 TEM-1 CTX-M-15 OXA-1 
K.pnenumoniae VR E165  aac(6’)-Ib-cr col E, F neg neg CTX-M-15 OXA-1 
K.pnenumoniae VR E176  aac(6’)-Ib-cr col E neg neg CTX-M-15 OXA-1 
K.pnenumoniae V29 aac(6’)-Ib-cr col E SHV-11 TEM-1 CTX-M-15 OXA-1 
K.pnenumoniae V91 aac(6’)-Ib-cr col E SHV-11 TEM-1 CTX-M-15 OXA-1 
  
 
    
P.mirabilis  T40 aac(6’)-Ib-cr Fia, F neg TEM-52 neg OXA-1 
  
 
    
M.morganii T53 aac(6’)-Ib-cr Untypeable neg neg CTX-M-15 OXA-1 
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Table 17. The aac(6’)-Ib-cr variant positive E. coli strains their beta-lactamase genes and 
incompatibility groups 
 
Strain PMQR inc type SHV TEM CTX-M OXA 
E. coli  T6 aac(6’)-Ib-cr Fia, Fib neg neg CTX-M-15 OXA-1 
E. coli  T10 aac(6’)-Ib-cr Fia neg neg CTX-M-15 OXA-1 
E. coli  T27 aac(6’)-Ib-cr Fia neg TEM-1 CTX-M-15 OXA-1 
E. coli  T30 aac(6’)-Ib-cr Fia, col E neg neg neg OXA-1 
E. coli  T39 aac(6’)-Ib-cr Fia neg TEM-1 CTX-M-15 OXA-1 
E. coli  T47 aac(6’)-Ib-cr Fia, F neg TEM-1 CTX-M-15 OXA-1 
E. coli  T87 aac(6’)-Ib-cr Fia, Fib, F, col E neg TEM-1 CTX-M-15 OXA-1 
E. coli  V18 aac(6’)-Ib-cr Fia, F neg neg CTX-M-15 OXA-1 
E. coli  V21 aac(6’)-Ib-cr Fia, F, col E neg neg CTX-M-15 OXA-1 
E. coli  V25 aac(6’)-Ib-cr Fia, F neg neg neg OXA-1 
E. coli  V27 aac(6’)-Ib-cr Fia, Fib, F, col E neg neg CTX-M-15 OXA-1 
E. coli  V32 aac(6’)-Ib-cr Fia, F neg neg neg OXA-1 
E. coli  V41 aac(6’)-Ib-cr Fia, F neg TEM-1 neg OXA-1 
E. coli  V47 aac(6’)-Ib-cr Fia, F neg neg CTX-M-15 OXA-1 
E. coli  V55 aac(6’)-Ib-cr Fia, F neg neg CTX-M-15 OXA-1 
E. coli  V65 aac(6’)-Ib-cr Fia, F neg neg neg OXA-1 
E. coli  V85 aac(6’)-Ib-cr Fia, F neg neg neg OXA-1 
E. coli  B33 aac(6’)-Ib-cr Fia, Fib, P, Fic neg neg neg OXA-1 
E. coli  B38 aac(6’)-Ib-cr Fia, col E, P neg neg CTX-M-15 OXA-1 
E. coli  B44 aac(6’)-Ib-cr Fia, Fib neg neg CTX-M-15 OXA-1 
E. coli  B65 qnrS1, aac(6’)-Ib-cr N, Fia, F, colE                                  neg TEM-1 CTX-M-15 OXA-1 
E. coli  R25 aac(6’)-Ib-cr Fia, F neg TEM-1 CTX-M-15 OXA-1 
E. coli VR B18 aac(6’)-Ib-cr Fia, F neg TEM-1 CTX-M-15 OXA-1 
E. coli VR B88 aac(6’)-Ib-cr Fia, Fib, F neg TEM-1 CTX-M-15 OXA-1 
E. coli VR B127 aac(6’)-Ib-cr col E, F neg TEM-1 neg OXA-1 
E. coli VR 227 aac(6’)-Ib-cr Fia, F neg TEM-1 CTX-M-15 OXA-1 
E. coli VR 232 aac(6’)-Ib-cr Fia, F neg neg CTX-M-15 OXA-1 
E. coli VR B248 aac(6’)-Ib-cr Fia, F neg TEM-1 neg OXA-1 
E. coli VR B262 aac(6’)-Ib-cr Fia, F neg TEM-1 neg OXA-1 
E. coli VR B269 aac(6’)-Ib-cr Fia, F neg TEM-1 CTX-M-15 OXA-1 
E. coli VR B292 aac(6’)-Ib-cr Fia, Fib, F neg TEM-1 neg OXA-1 
E. coli VR B649 aac(6’)-Ib-cr Fia, Fib, F neg neg neg OXA-1 
E. coli VR B656 aac(6’)-Ib-cr Fia, F neg TEM-1 CTX-M-15 OXA-1 
E. coli VR B715 aac(6’)-Ib-cr Fia, F neg TEM-1 CTX-M-15 OXA-1 
E. coli VR B 717 aac(6’)-Ib-cr Fia, F neg neg CTX-M-15 OXA-1 
E. coli VR B754 aac(6’)-Ib-cr Fia, F neg neg neg OXA-1 
E. coli VR B770 qnrS1, aac(6’)-Ib-cr N, FIA, F  neg TEM-1 CTX-M-15 OXA-1 
E. coli VR B775 qnrS1, aac(6’)-Ib-cr N, FIA, F  neg TEM-1 CTX-M-15 OXA-1 
E. coli VR B780 aac(6’)-Ib-cr Fia, Fib neg TEM-1 CTX-M-15 OXA-1 
E. coli VR B784 aac(6’)-Ib-cr Fia, F neg TEM-1 neg OXA-1 
E. coli VR B786 aac(6’)-Ib-cr Fia, F neg TEM-1 neg neg 
E. coli VR B787 aac(6’)-Ib-cr Fia, F neg TEM-1 CTX-M-15 OXA-1 
E. coli VR B793 aac(6’)-Ib-cr Fia, Fib, F neg neg CTX-M-15 OXA-1 
E. coli VR B808 aac(6’)-Ib-cr Fia, col E, F neg TEM-1 CTX-M-15 OXA-1 
E. coli VR B814 qnrS1, aac(6’)-Ib-cr N, FIA, F neg TEM-1 CTX-M-15 OXA-1 
E. coli VR C17 aac(6’)-Ib-cr Fia, Fib, F neg neg neg OXA-1 
E. coli VR C18 aac(6’)-Ib-cr Fia, Fib neg TEM-1 CTX-M-15 OXA-1 
E. coli VR C19 aac(6’)-Ib-cr Fia, Fib, F neg TEM-1 CTX-M-15 OXA-1 
E. coli VR C24 aac(6’)-Ib-cr Fia, F neg TEM-1 CTX-M-15 OXA-1 
E. coli VR C66 aac(6’)-Ib-cr Fia, Fib, F neg neg CTX-M-15 OXA-1 
E. coli VR C93 aac(6’)-Ib-cr Fia, F neg neg neg OXA-1 
E. coli VR C105 aac(6’)-Ib-cr Fia, Fib, F neg neg CTX-M-15 OXA-1 
E. coli VR C109 aac(6’)-Ib-cr Fia, Fib, F neg neg CTX-M-15 OXA-1 
E. coli VR E13 aac(6’)-Ib-cr Fia, Fib, F neg TEM-1 CTX-M-15 OXA-1 
E. coli VR E25 aac(6’)-Ib-cr Fia, F neg TEM-1 CTX-M-15 OXA-1 
E. coli VR E39 aac(6’)-Ib-cr Fia, Fib, F neg TEM-1 CTX-M-15 OXA-1 
E. coli VR E47 aac(6’)-Ib-cr Fia, Fib, F neg neg neg OXA-1 
E. coli VR E64 aac(6’)-Ib-cr F neg neg CTX-M-15 OXA-1 
E. coli VR E98 aac(6’)-Ib-cr Fia, Fib, F neg TEM-1 CTX-M-15 OXA-1 
E. coli VR E108 aac(6’)-Ib-cr Fia, F neg TEM-1 CTX-M-15 OXA-1 
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Figure 22. Aminoacid sequence alignament of aac(6’)-Ib-cr variant enzymes in our collection. 
Characteristic aminoacid substitutions at Trp102Arg and Asp179Tyr are highlighted and 
compared to the AAL93141 wild-type aac(6’)-Ib. 
 
 
 
 
 
 
                                  102                                                                         179 
AAL93141 PSVLAQESVTPYIAMLNGEPIGYAQSYVALGSGDGWWEEETDPGVRGIDQLLANASQLGKGLGTKLVRALVELLFNDPEVTKIQTDPSPSNLRAIRCYEKAGFERQGTVTTPDGPAVYMVQTR 
 T6      PSVLAQESVTPYIAMLNGEPIGYAQSYVALGSGDGRWEEETDPGVRGIDQLLANASQLGKGLGTKLVRALVELLFNDPEVTKIQTDPSPSNLRAIRCYEKAGFERQGTVTTPYGPAVYMVQTR 
 T10     PSVLAQESVTPYIAMLNGEPIGYAQSYVALGSGDGRWEEETDPGVRGIDQLLANASQLGKGLGTKLVRALVELLFNDPEVTKIQTDPSPSNLRAIRCYEKAGFERQGTVTTPYGPAVYMVQTR 
 T27     PSVLAQESVTPYIAMLNGEPIGYAQSYVALGSGDGRWEEETDPGVRGIDQLLANASQLGKGLGTKLVRALVELLFNDPEVTKIQTDPSPSNLRAIRCYEKAGFERQGTVTTPYGPAVYMVQTR 
 T30     PSVLAQESVTPYIAMLNGEPIGYAQSYVALGSGDGRWEEETDPGVRGIDQLLANASQLGKGLGTKLVRALVELLFNDPEVTKIQTDPSPSNLRAIRCYEKAGFERQGTVTTPYGPAVYMVQTR 
 T39     PSVLAQESVTPYIAMLNGEPIGYAQSYVALGSGDGRWEEETDPGVRGIDQLLANASQLGKGLGTKLVRALVELLFNDPEVTKIQTDPSPSNLRAIRCYEKAGFERQGTVTTPYGPAVYMVQTR 
 T40     PSVLAQESVTPYIAMLNGEPIGYAQSYVALGSGDGRWEEETDPGVRGIDQLLANASQLGKGLGTKLVRALVELLFNDPEVTKIQTDPSPSNLRAIRCYEKAGFERQGTVTTPYGPAVYMVQTR 
 T47     PSVLAQESVTPYIAMLNGEPIGYAQSYVALGSGDGRWEEETDPGVRGIDQLLANASQLGKGLGTKLVRALVELLFNDPEVTKIQTDPSPSNLRAIRCYEKAGFERQGTVTTPYGPAVYMVQTR 
 T53     PSVLAQESVTPYIAMLNGEPIGYAQSYVALGSGDGRWEEETDPGVRGIDQLLANASQLGKGLGTKLVRALVELLFNDPEVTKIQTDPSPSNLRAIRCYEKAGFERQGTVTTPYGPAVYMVQTR 
 T87     PSVLAQESVTPYIAMLNGEPIGYAQSYVALGSGDGRWEEETDPGVRGIDQLLANASQLGKGLGTKLVRALVELLFNDPEVTKIQTDPSPSNLRAIRCYEKAGFERQGTVTTPYGPAVYMVQTR 
 V18     PSVLAQESVTPYIAMLNGEPIGYAQSYVALGSGDGRWEEETDPGVRGIDQLLANASQLGKGLGTKLVRALVELLFNDPEVTKIQTDPSPSNLRAIRCYEKAGFERQGTVTTPYGPAVYMVQTR 
 V21     PSVLAQESVTPYIAMLNGEPIGYAQSYVALGSGDGRWEEETDPGVRGIDQLLANASQLGKGLGTKLVRALVELLFNDPEVTKIQTDPSPSNLRAIRCYEKAGFERQGTVTTPYGPAVYMVQTR 
 V25     PSVLAQESVTPYIAMLNGEPIGYAQSYVALGSGDGRWEEETDPGVRGIDQLLANASQLGKGLGTKLVRALVELLFNDPEVTKIQTDPSPSNLRAIRCYEKAGFERQGTVTTPYGPAVYMVQTR 
 V27     PSVLAQESVTPYIAMLNGEPIGYAQSYVALGSGDGRWEEETDPGVRGIDQLLANASQLGKGLGTKLVRALVELLFNDPEVTKIQTDPSPSNLRAIRCYEKAGFERQGTVTTPYGPAVYMVQTR 
 V29     PSVLAQESVTPYIAMLNGEPIGYAQSYVALGSGDGRWEEETDPGVRGIDQLLANASQLGKGLGTKLVRALVELLFNDPEVTKIQTDPSPSNLRAIRCYEKAGFERQGTVTTPYGPAVYMVQTR 
 V32     PSVLAQESVTPYIAMLNGEPIGYAQSYVALGSGDGRWEEETDPGVRGIDQLLANASQLGKGLGTKLVRALVELLFNDPEVTKIQTDPSPSNLRAIRCYEKAGFERQGTVTTPYGPAVYMVQTR 
 V41     PSVLAQESVTPYIAMLNGEPIGYAQSYVALGSGDGRWEEETDPGVRGIDQLLANASQLGKGLGTKLVRALVELLFNDPEVTKIQTDPSPSNLRAIRCYEKAGFERQGTVTTPYGPAVYMVQTR 
 V47     PSVLAQESVTPYIAMLNGEPIGYAQSYVALGSGDGRWEEETDPGVRGIDQLLANASQLGKGLGTKLVRALVELLFNDPEVTKIQTDPSPSNLRAIRCYEKAGFERQGTVTTPYGPAVYMVQTR 
 V55     PSVLAQESVTPYIAMLNGEPIGYAQSYVALGSGDGRWEEETDPGVRGIDQLLANASQLGKGLGTKLVRALVELLFNDPEVTKIQTDPSPSNLRAIRCYEKAGFERQGTVTTPYGPAVYMVQTR 
 V65     PSVLAQESVTPYIAMLNGEPIGYAQSYVALGSGDGRWEEETDPGVRGIDQLLANASQLGKGLGTKLVRALVELLFNDPEVTKIQTDPSPSNLRAIRCYEKAGFERQGTVTTPYGPAVYMVQTR 
 V85     PSVLAQESVTPYIAMLNGEPIGYAQSYVALGSGDGRWEEETDPGVRGIDQLLANASQLGKGLGTKLVRALVELLFNDPEVTKIQTDPSPSNLRAIRCYEKAGFERQGTVTTPYGPAVYMVQTR 
 V91     PSVLAQESVTPYIAMLNGEPIGYAQSYVALGSGDGRWEEETDPGVRGIDQLLANASQLGKGLGTKLVRALVELLFNDPEVTKIQTDPSPSNLRAIRCYEKAGFERQGTVTTPYGPAVYMVQTR 
 B33     PSVLAQESVTPYIAMLNGEPIGYAQSYVALGSGDGRWEEETDPGVRGIDQLLANASQLGKGLGTKLVRALVELLFNDPEVTKIQTDPSPSNLRAIRCYEKAGFERQGTVTTPYGPAVYMVQTR 
 B38     PSVLAQESVTPYIAMLNGEPIGYAQSYVALGSGDGRWEEETDPGVRGIDQLLANASQLGKGLGTKLVRALVELLFNDPEVTKIQTDPSPSNLRAIRCYEKAGFERQGTVTTPYGPAVYMVQTR 
 B44     PSVLAQESVTPYIAMLNGEPIGYAQSYVALGSGDGRWEEETDPGVRGIDQLLANASQLGKGLGTKLVRALVELLFNDPEVTKIQTDPSPSNLRAIRCYEKAGFERQGTVTTPYGPAVYMVQTR 
 B65     PSVLAQESVTPYIAMLNGEPIGYAQSYVALGSGDGRWEEETDPGVRGIDQLLANASQLGKGLGTKLVRALVELLFNDPEVTKIQTDPSPSNLRAIRCYEKAGFERQGTVTTPYGPAVYMVQTR 
 R25     PSVLAQESVTPYIAMLNGEPIGYAQSYVALGSGDGRWEEETDPGVRGIDQLLANASQLGKGLGTKLVRALVELLFNDPEVTKIQTDPSPSNLRAIRCYEKAGFERQGTVTTPYGPAVYMVQTR 
VRB18    PSVLAQESVTPYIAMLNGEPIGYAQSYVALGSGDGRWEEETDPGVRGIDQLLANASQLGKGLGTKLVRALVELLFNDPEVTKIQTDPSPSNLRAIRCYEKAGFERQGTVTTPYGPAVYMVQTR 
VRB88    PSVLAQESVTPYIAMLNGEPIGYAQSYVALGSGDGRWEEETDPGVRGIDQLLANASQLGKGLGTKLVRALVELLFNDPEVTKIQTDPSPSNLRAIRCYEKAGFERQGTVTTPYGPAVYMVQTR 
VRB127   PSVLAQESVTPYIAMLNGEPIGYAQSYVALGSGDGRWEEETDPGVRGIDQLLANASQLGKGLGTKLVRALVELLFNDPEVTKIQTDPSPSNLRAIRCYEKAGFERQGTVTTPYGPAVYMVQTR 
VRB227   PSVLAQESVTPYIAMLNGEPIGYAQSYVALGSGDGRWEEETDPGVRGIDQLLANASQLGKGLGTKLVRALVELLFNDPEVTKIQTDPSPSNLRAIRCYEKAGFERQGTVTTPYGPAVYMVQTR 
VRB232   PSVLAQESVTPYIAMLNGEPIGYAQSYVALGSGDGRWEEETDPGVRGIDQLLANASQLGKGLGTKLVRALVELLFNDPEVTKIQTDPSPSNLRAIRCYEKAGFERQGTVTTPYGPAVYMVQTR 
VRB248   PSVLAQESVTPYIAMLNGEPIGYAQSYVALGSGDGRWEEETDPGVRGIDQLLANASQLGKGLGTKLVRALVELLFNDPEVTKIQTDPSPSNLRAIRCYEKAGFERQGTVTTPYGPAVYMVQTR 
VRB262   PSVLAQESVTPYIAMLNGEPIGYAQSYVALGSGDGRWEEETDPGVRGIDQLLANASQLGKGLGTKLVRALVELLFNDPEVTKIQTDPSPSNLRAIRCYEKAGFERQGTVTTPYGPAVYMVQTR 
         VRB269   PSVLAQESVTPYIAMLNGEPIGYAQSYVALGSGDGRWEEETDPGVRGIDQLLANASQLGKGLGTKLVRALVELLFNDPEVTKIQTDPSPSNLRAIRCYEKAGFERQGTVTTPYGPAVYMVQTR 
         VRB292   PSVLAQESVTPYIAMLNGEPIGYAQSYVALGSGDGRWEEETDPGVRGIDQLLANASQLGKGLGTKLVRALVELLFNDPEVTKIQTDPSPSNLRAIRCYEKAGFERQGTVTTPYGPAVYMVQTR 
         VRB649   PSVLAQESVTPYIAMLNGEPIGYAQSYVALGSGDGRWEEETDPGVRGIDQLLANASQLGKGLGTKLVRALVELLFNDPEVTKIQTDPSPSNLRAIRCYEKAGFERQGTVTTPYGPAVYMVQTR 
VRB656   PSVLAQESVTPYIAMLNGEPIGYAQSYVALGSGDGRWEEETDPGVRGIDQLLANASQLGKGLGTKLVRALVELLFNDPEVTKIQTDPSPSNLRAIRCYEKAGFERQGTVTTPYGPAVYMVQTR 
         VRB715   PSVLAQESVTPYIAMLNGEPIGYAQSYVALGSGDGRWEEETDPGVRGIDQLLANASQLGKGLGTKLVRALVELLFNDPEVTKIQTDPSPSNLRAIRCYEKAGFERQGTVTTPYGPAVYMVQTR 
         VRB717   PSVLAQESVTPYIAMLNGEPIGYAQSYVALGSGDGRWEEETDPGVRGIDQLLANASQLGKGLGTKLVRALVELLFNDPEVTKIQTDPSPSNLRAIRCYEKAGFERQGTVTTPYGPAVYMVQTR 
         VRB754   PSVLAQESVTPYIAMLNGEPIGYAQSYVALGSGDGRWEEETDPGVRGIDQLLANASQLGKGLGTKLVRALVELLFNDPEVTKIQTDPSPSNLRAIRCYEKAGFERQGTVTTPYGPAVYMVQTR 
         VRB770   PSVLAQESVTPYIAMLNGEPIGYAQSYVALGSGDGRWEEETDPGVRGIDQLLANASQLGKGLGTKLVRALVELLFNDPEVTKIQTDPSPSNLRAIRCYEKAGFERQGTVTTPYGPAVYMVQTR 
         VRB775   PSVLAQESVTPYIAMLNGEPIGYAQSYVALGSGDGRWEEETDPGVRGIDQLLANASQLGKGLGTKLVRALVELLFNDPEVTKIQTDPSPSNLRAIRCYEKAGFERQGTVTTPYGPAVYMVQTR 
         VRB780   PSVLAQESVTPYIAMLNGEPIGYAQSYVALGSGDGRWEEETDPGVRGIDQLLANASQLGKGLGTKLVRALVELLFNDPEVTKIQTDPSPSNLRAIRCYEKAGFERQGTVTTPYGPAVYMVQTR 
         VRB784   PSVLAQESVTPYIAMLNGEPIGYAQSYVALGSGDGRWEEETDPGVRGIDQLLANASQLGKGLGTKLVRALVELLFNDPEVTKIQTDPSPSNLRAIRCYEKAGFERQGTVTTPYGPAVYMVQTR 
         VRB786   PSVLAQESVTPYIAMLNGEPIGYAQSYVALGSGDGRWEEETDPGVRGIDQLLANASQLGKGLGTKLVRALVELLFNDPEVTKIQTDPSPSNLRAIRCYEKAGFERQGTVTTPYGPAVYMVQTR 
         VRB787   PSVLAQESVTPYIAMLNGEPIGYAQSYVALGSGDGRWEEETDPGVRGIDQLLANASQLGKGLGTKLVRALVELLFNDPEVTKIQTDPSPSNLRAIRCYEKAGFERQGTVTTPYGPAVYMVQTR 
         VRB793   PSVLAQESVTPYIAMLNGEPIGYAQSYVALGSGDGRWEEETDPGVRGIDQLLANASQLGKGLGTKLVRALVELLFNDPEVTKIQTDPSPSNLRAIRCYEKAGFERQGTVTTPYGPAVYMVQTR 
         VRB808   PSVLAQESVTPYIAMLNGEPIGYAQSYVALGSGDGRWEEETDPGVRGIDQLLANASQLGKGLGTKLVRALVELLFNDPEVTKIQTDPSPSNLRAIRCYEKAGFERQGTVTTPYGPAVYMVQTR 
         VRB814   PSVLAQESVTPYIAMLNGEPIGYAQSYVALGSGDGRWEEETDPGVRGIDQLLANASQLGKGLGTKLVRALVELLFNDPEVTKIQTDPSPSNLRAIRCYEKAGFERQGTVTTPYGPAVYMVQTR  
VRC17    PSVLAQESVTPYIAMLNGEPIGYAQSYVALGSGDGRWEEETDPGVRGIDQLLANASQLGKGLGTKLVRALVELLFNDPEVTKIQTDPSPSNLRAIRCYEKAGFERQGTVTTPYGPAVYMVQTR 
         VRC18    PSVLAQESVTPYIAMLNGEPIGYAQSYVALGSGDGRWEEETDPGVRGIDQLLANASQLGKGLGTKLVRALVELLFNDPEVTKIQTDPSPSNLRAIRCYEKAGFERQGTVTTPYGPAVYMVQTR 
         VRC19    PSVLAQESVTPYIAMLNGEPIGYAQSYVALGSGDGRWEEETDPGVRGIDQLLANASQLGKGLGTKLVRALVELLFNDPEVTKIQTDPSPSNLRAIRCYEKAGFERQGTVTTPYGPAVYMVQTR 
         VRC24    PSVLAQESVTPYIAMLNGEPIGYAQSYVALGSGDGRWEEETDPGVRGIDQLLANASQLGKGLGTKLVRALVELLFNDPEVTKIQTDPSPSNLRAIRCYEKAGFERQGTVTTPYGPAVYMVQTR 
         VRC66    PSVLAQESVTPYIAMLNGEPIGYAQSYVALGSGDGRWEEETDPGVRGIDQLLANASQLGKGLGTKLVRALVELLFNDPEVTKIQTDPSPSNLRAIRCYEKAGFERQGTVTTPYGPAVYMVQTR 
         VRC93    PSVLAQESVTPYIAMLNGEPIGYAQSYVALGSGDGRWEEETDPGVRGIDQLLANASQLGKGLGTKLVRALVELLFNDPEVTKIQTDPSPSNLRAIRCYEKAGFERQGTVTTPYGPAVYMVQTR 
         VRC105   PSVLAQESVTPYIAMLNGEPIGYAQSYVALGSGDGRWEEETDPGVRGIDQLLANASQLGKGLGTKLVRALVELLFNDPEVTKIQTDPSPSNLRAIRCYEKAGFERQGTVTTPYGPAVYMVQTR 
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5.   Conclusion and discussion 
 
The survey for plasmid-mediated quinolone resistance determinants demonstrates a 14.3% 
(108/756) prevelance in our collection of clinical Enterobacteriaceae isolates from North-East 
Italy. These determinants were found in 104 isolates, since four E. coli strains carried qnrS1 and 
aac(6’)-Ib-cr variant too. Among the qnr genes 5.02 % (38/756) were positive; qnrS, qnrB and 
qnrD were detected, neither qnrA nor qnrC were found. 
Four P. mirabilis and one M. morganii were positive for qnrD. These are the first qnrD genes in 
Europe, and the first ever qnr determinant found in M. morgani. Earlier this determinant was 
reported only from China, in four Salmonella enterica Serovar Bovismorbificans and Kentucky 
clinical isolates (40). The sequences of these qnrD genes were found to be 100% the same as in 
the first described allel. The sequence analysis of the five qnrD-harbouring plasmids showed 
1450 bp of 2687 bp (54%) to be same as the first described plasmid, where the qnrD gene 
together with its upstream localized promoter region tends to be conserved. In the downstream 
sequence Orf2 was localized on each of the plasmids, without additional information about its 
function. The remaining sequences (1237 bp, i.e. 46% of the plasmid) was unknown. All qnrD 
plasmids lacked replication gene, suggesting chromosal support for the replication, moreover 
genes for horizontal transfer were also not identified. 
Among all isolates, 26 qnrS1 positive were identified, namely fifteen Klebsiella spp, ten E.coli 
and one P. mirabilis. Their plasmid profile was analyzed and incN replicon type, which carried 
the qnrS1 gene, was the dominant. Association of qnrS1 and blaVIM-1 metallo beta-lactamase is 
remarkable, and it was found in one E. coli and five Klebsiella spp. Among them, three incN 
plasmids carrying both blaVIM-1 and qnrS1 detected in three K. pneumoniae isolates were found to 
be conjugable. This is an alarmig phenomenon, since these plasmids are capable to spread 
between different species. 
Our survey found the first LAP narrow-spectrum beta-lactamase in Italy, in three qnrS1 positive 
K. pneumoniae ST147 strains. The blaLAP-2 gene was incorporated with qnrS1 in genetic context 
named, ISEcl2. LAP beta-lactamase was first identified in six Enterobacter cloacae clinical 
isolates from France and Vietnam (64). The complex genetic material, ISEcl2 together with 
qnrS1 and blaLAP-2 can explain of co-selection towards resistance of narrow-spectrum beta-lactam 
and fluoroquinolone antibiotics. 
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In the case of qnrB, Citrobacter freundii carries qnrB6, while Citrobacter koseri carries qnrB19, 
and 2 Enterobacter spp. were positive for qnrB2. The qnrB carriage in Citrobacter spp. is 
common (38). 
Screening for aac(6’)-Ib-cr shows high prevalence in E. coli, 60 from the 70 positive isolates 
(85.7%) belong to this species. Interestingly, four E. coli strain harboured two PMQR genes, 
qnrS1 and aac(6’)-Ib-cr simultaneously. 
None of the quinolone specific efflux pumps (qepA and oqxA) were found in our collection. This 
is not surprising since these determinants are rarely found worldwide. QepA was detected first in 
Japan and later in isolates from France and Belgium (20, 46, 47). The oqxAB was detected only 
in one clinical E. coli and K. pneumonaie in South-Korea and in environmental isolates from 
China (35, 50). 
The ciprofloxacin MIC distribution showed the qnr positive isolates to coincide with both 
susceptible and resistant values, while aac(6’)-Ib-cr variant positive strains could only be found 
among highly resistant phenotype. This data show that qnr positive strains do not have a common 
phenotype and, their prevalence is underestimeted when resistance breakpoints are used as 
markers. 
In our survey, the detected plasmids harbouring quinolone-resistance determinants were analyzed 
by replicon typing and it showed that these plasmids are able to replicate in Enterobactericeae. 
PMQR positive strains are clonaly unrelated as we detected by means of PFGE for qnrS1 positive 
E.coli isolates and RAPD technique for qnrD positive P. mirabilis confirmed. 
The landscape of fluoroquinolone resistance is getting diverse. Besides the chromosomal 
mutations leading to high-level fluroquinolone resistance, we can point out the low-level 
resistance as well. This latter phenotype is maintained by plasmid-coded quinolone resistance 
determinants and play a role in selection of higher-level resistance. MIC values alone will not 
give enough infomation about resistance mechanisms. Molecular screening of at-risk isolates 
seems mandatory.  
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6. Abstract (English) 
 
Clinical isolates of fluoroquinolone-resistant Enterobacteriaceae are emerging worldwide. The 
traditional resistance mechanism is the accumulation of mutations in the chromosome coding for 
the target molecules of fluoroquinolone. All known plasmid-mediated quinolone resistance 
determinants - namely, Qnr determinants, aac(6’)-Ib-cr enzyme, qepA and oqxAB efflux pumps - 
can individually confer low-level resistance. In this condition, bacterial cells have increased 
mutation frequency, making it easier the selection of higher-level fluoroquinolone resistance. 
Our aims were to survey for plasmid-mediated quinolone resistance determinants a collection of 
Enterobacteriaceae clinical isolates originating from clinical microbiological laboratories of 
North-East Italy, and to characterize both the resistant strains and the plasmids harbouring 
quinolone resistance determinants and beta-lactamase genes. 
Altogether, 756 Enterobacteriaceae clinical isolates were collected: 497 Escherichia coli, 68 
Klebsiella spp., 18 Citrobacter spp., 69 Proteus spp., 24 Morganella spp., 21 Providencia spp., 
52 Enterobacter spp. and 7 Serratia marcescens. MIC values were determined by microdilution 
for ciprofloxacin and levofloxacin, showing values between 0.06 and 128 µg/ml. Screening by 
PCR for plasmid-mediated quinolone resistance determinants yielded 108 positives [38 qnr and 
70 aac(6’)-Ib-cr] out of 104 isolates. Sequencing and analysis of PCR-positive products verified: 
26 qnrS1, 2 qnrB2, 2 qnrB6, 2 qnrB8, 1 qnrB19 and 5 qnrD. Four Proteus mirabilis and one 
Morganella morganii isolates were qnrD positive. Plasmid extraction was performed, and 
Southern blot analysis verified the plasmid localization of the qnrD determinants. Inverse PCR-
based sequencing of qnrD-harbouring plasmids, resulted in a 2687 bp and 2684 bp plasmid DNA 
for Proteus mirabilis and Morganella morganii, respectively. Both plasmid sequences are 
deposited at Genbank with accession numbers JN183060 and JN183061. Among the qnrS1 
positive isolates, 10 E. coli, 15 Klebsiella spp. and one Proteus mirabilis were detected. 
Detection of beta-lactamase genes by PCR and sequencing yielded: 6 VIM-1, 7 SHV-12 and 3 
LAP-2 positives. All four qnrS1 E. coli with the aac(6’)-Ib-cr variant were CTX-M-15, OXA-1 
and TEM-1 positive. PCR-based replicon typing found incN type plasmid to be the most 
prevalent. Conjugation experiment found 3 qnrS1 and VIM-1 harbouring conjugable plasmids. 
We could also demonstrate in three Klebsiella pneumoniae ST147 strains that qnrS1 and blaLAP-2 
are integrated in the same ISEcl2 genetic context. Southern blot verified that the qnrS1 gene is 
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localized on incN or untypeable plasmids. Altogether 70 aac(6’)-Ib-cr variant positive isolates 
were found: 60 E. coli, 8 Klebsiella spp., one P.mirabilis and one M.morganii. Replicon typing of 
plasmids found incFia and incF types to be common for E. coli and P. mirabilis while incColE 
type to be predominant in Klebsiella spp., whilst M.morganii was untypeable. A high correlation 
of the aac(6)-Ib-cr variant with OXA-1 and CTX-M-15 beta-lactamases was found in E. coli 
(42/60) and in Klebsiella spp. (8/8), whilst in P. mirabilis the aac(6)-Ib-cr variant was associated 
with TEM-52 and OXA-1. 
Our survey for plasmid-mediated quinolone resistance determinants found a 13.7% prevalence 
(104/756). MIC values for ciprofloxacin and levofloxacin showed uneven resistance levels 
among the qnr-positive isolates, with only 13.1% of strains (5/38) in the range of low-level 
resistance, while in case of the aac(6’)-Ib-cr variant all positive isolates were resistant to 
fluoroquinolones. Our survey found the first qnrD determinants in Europe, and we could also 
demonstrate the first LAP-2 beta-lactamase in Italy. 
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7. Abstract (Italian) 
 
In tutto il mondo si sta assistendo ad un aumento dell’incidenza di isolati clinici di 
Enterobacteriaceae resistenti ai fluorochinoloni. 
La resistenza può essere dovuta ad un accumulo di mutazioni cromosomiche a livello dei geni 
che codificano le topoisomerasi, bersaglio d’azione dei fluorochinoloni; mediata da determinanti 
plasmidici, in particolare quelli che codificano per proteine di protezione Qnr, per l’enzima di 
acetilazione aac(6’)-Ib-cr e per le pompe di efflusso QepA e OqxAB. Tutti questi determinanti da 
soli conferiscono al batterio bassi livelli di resistenza ma consentono un aumento della frequenza 
di mutazione,facilitando la selezione di alti livelli di resistenza. 
Lo scopo di questo lavoro è stato quello di valutare l’incidenza della presenza di determinanti 
plasmidici che mediano la resistenza ai fluorochinoloni (PMQR), in una collezione di isolati 
clinici di Enterobacteriaceae provenienti da vari laboratori del nord-est Italia. Tutti i ceppi 
risultati positivi per la presenza di questi determinanti sono stati caratterizzati dal punto di vista 
plasmidico e correlati alla presenza di geni che codificano per beta-lattamasi. 
Sono stati raccolti 756 isolati clinici di enterobatteri: 497 Escherichia coli, 68 Klebsiella spp., 18 
Citrobacter spp., 69 Proteus spp., 24 Morganella spp., 21 Providencia spp., 52 Enterobacter spp. 
and 7 Serratia marcescens. 
Per tutti i ceppi sono stati eseguiti i saggi di sensibilità con il metodo della microdiluizione a 
ciprofloxacina e levofloxacina, ottenendo valori di MIC variabili da 0.06 a 128 µg/ml. 
Lo screening dei PMQR mediante PCR ha evidenziato 108 positivi (38 qnr e 70 aac(6’)-Ib-cr) su 
104 isolati. L’analisi delle sequenze degli ampliconi ha permesso di classificare le varianti qnr  in 
26 qnrS1, 2 qnrB2, 2 qnrB6, 2 qnrB8, 1 qnrB19 e 5 qnrD. Per quest’ultimo determinante sono 
risultati positivi 4 P. mirabilis e una M. morganii verificandone la localizzazione plasmidica con 
Southern blot e ottenendo la sequenza completa mediante PCR inversa (2687 bp per P. mirabilis 
e 2684 bp per M. morganii depositate in Genbank con i numeri di accesso JN183060 and 
JN183061). 
I ceppi positivi per qnrS1 erano suddivisi in 10 E. coli, 15 Klebsiella spp. e un P. mirabilis. In 
questi ceppi qnrS1 era accompagnato da VIM-1, SHV-12 e LAP-2. I 4 E. coli che ospitavano sia 
qnrS1 che aac(6’)-Ib-cr ospitavano anche  CTX-M-15, OXA-1 and TEM-1. 
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I plasmidi dei positivi  sono stati caratterizzati con il metodo dell’origine della replicazione. I 
ceppi qnrS1 ospitano questo gene su plasmidi di tipo incN. Con esperimenti di coniugazione si è 
visto che  il plasmide con qnrS1 e VIM-1 è coniugabile. Inoltre, nei tre ceppi di K. pneumoniae 
ST147 con qnrS1 e blaLAP-2 si è dimostrato che questi sono integrati nello stesso contesto 
genetico di ISEcl2. 
I 70 ceppi che presentano la variante aac(6’)-Ib-cr erano suddivisi in 60 E. coli, 8 Klebsiella spp., 
1 P. mirabilis e 1 M. morganii. La tipizzazione dei plasmidi ha messo in evidenza i tipi incFia e 
incF sia in  E. coli che P. mirabilis, mentre incColE era predominante in Klebsiella spp. e  M. 
morganii era caratterizzata da un plasmide non tipizzabile. Si è inoltre evidenziata una alta 
correlazione fra la variante aac(6)-Ib-cr e le beta-lattamasi OXA-1 e CTX-M-15 sia in  E. coli 
(42/60), che in Klebsiella spp. (8/8), con l’eccezione di P. mirabilis dove  invece con OXA-1 è 
presente TEM-52. 
Dalla nostra indagine è emersa una prevalenza di determinanti plasmidici che mediano la 
resistenza ai fluorochinoloni del 13.7% (104/756). Solo il 13.1% (5/38) degli isolati positivi per il 
qnr risultano in un range di bassa resistenza,  mentre i ceppi positivi per la variante aac(6’)-Ib-cr 
presentavano tutti alti livelli di resistenza. 
La nostra indagine ha consentito di descrivere il primo determinante qnrD isolato in Europa e la 
prima beta-lattamasi LAP-2 isolata in Italia. 
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